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Abstract 
Therapeutic angiogenesis has emerged as a novel treatment approach for ischemic vascular 
diseases. It relies on the delivery of exogenous growth factors to stimulate neovessel formation. 
However, systemic administration of angiogenic factors results in rapid clearance from the site 
of interest due to their short biological half-life. Mimicking the angiogenesis process is 
multifaceted; therefore, therapeutic angiogenesis regimens should recapitulate both temporal 
and spatial presentation of multiple growth factors. In this work, controlled delivery of two 
growth factors, an angiogenic factor −fibroblast growth factor-2 (FGF2), and an arteriogenic 
factor −fibroblast growth factor-9 (FGF9), from biodegradable poly(ester amide) (PEA) 
electrospun fibers towards targeting neovascular formation and maturation, is reported.  
FGF2 and FGF9 were dual loaded into PEA fibers using a mixed blend and emulsion 
electrospinning technique. In vitro release kinetics of FGF2/FGF9 dual-loaded PEA fibers over 
a period of 70 days showed controlled and concurrent release of both factors in a bioactive 
form.  Matrigel tube formation and Boyden chamber transwell assays conducted to evaluate 
endothelial cell (EC) tube formation, directed smooth muscle cell (SMC) migration, and EC-
SMC interaction demonstrated that co-released FGF2 and FGF9 from dual loaded PEA fibers 
enhanced EC tube formation (p < 0.05), directed-migration of SMCs towards PDGF-BB (p < 
0.05), and EC/SMC tube stabilization. An ex ovo chick chorioallantoic membrane (CAM) 
model coupled with power Doppler ultrasound imaging, and an in vivo ischemic hindlimb 
mouse model were employed to assess the in vivo angiogenic capacity of the delivery system. 
The CAM assay did not show a significant increase in the vascular density of the full CAM 
surface treated with FGF2/FGF9 dual-loaded fibers (p > 0.05); however, the 3D power Doppler 
volumes displayed enhanced localized angiogenesis underneath the fibrous mats with 
enhanced blood perfusion and flow, as indicated by a statistically significant increase in 
vascularization and vascularization flow indices for the dual-loaded PEA fibers group versus 
the unloaded PEA fibers group (p < 0.05).  
In order to evaluate the effectiveness of FGF9-loaded PEA fibers in vivo, an ischemic hindlimb 
mouse model was used. Histological analysis of the ischemic tibialis anterior muscle revealed 
increased percentage of mural cell-covered microvessels in mice treated with FGF9-loaded 
PEA fibers than those treated with unloaded fibers.  Interestingly, CatWalk gait analysis 7 days 
 ii 
 
post-ischemia did not demonstrate superior restoration of the ischemic hindlimb function for 
the mice treated with FGF9-loaded PEA fibers, which might be too early for the healing of the 
injured limb. Taken together, the data in this thesis supports the premise that controlled 
delivery of fibroblast growth factors from biodegradable PEA electrospun fibers can provide 
means for minimally invasive revascularization of ischemic tissues as a novel approach for 
treatment of ischemic vascular diseases. 
 
Keywords  
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poly(ester amide)s (PEAs) fibers; Fibroblast growth factor-2 (FGF2); Fibroblast growth factor-9 
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Chapter 1  
1  Introduction 
 Overview 
A functional vasculature transports oxygen, nutrients and signals to organs and tissues in 
both healthy and diseased conditions. Ischemic vascular diseases including coronary heart 
disease and peripheral arterial disease reduce blood flow and subsequently cause ischemia. 
Considerable progress has been made in tackling cardiovascular disease in Canada over 
the past 60 years with death rates declining by more than 75%. This resulted in 165,000 
survivors in 2013; each one is a living proof on the importance of research in this area [1]. 
Despite this encouraging progress, there are 350,000 hospitalizations annually due to heart 
disease and stroke in Canada. Each year approximately 70,000 heart attacks and 50,000 
strokes send Canadians to emergency rooms [2]. Collectively, heart disease and stroke 
costs the Canadian economy more than $20.9 billion every year in terms of physician 
services, hospital costs, lost wages and decreased productivity [1, 3, 4]. 
Induction of neovessel formation (therapeutic angiogenesis) can offer a promising 
approach to treat many ischemic vascular conditions, especially coronary and peripheral 
arterial diseases [5]. Neovascularization can be achieved by three approaches: gene therapy 
by promoting the expression of angiogenic genes, protein therapy by supplying angiogenic 
growth factors, and cell therapy through delivering progenitor or stem cells. Protein 
delivery is the most straightforward strategy and is considered as an ‘off-the-shelf’ 
treatment. However, systemic administration of the soluble angiogenic growth factors 
results in their degradation and rapid clearance from the tissue of interest. Since neovessel 
formation and tissue regeneration usually take from weeks to months [6], unlike bolus 
delivery that provides a burst and short period of biological effects [5], controlled delivery 
of the angiogenic factor over a long-term in a sustained manner is needed to protect its 
bioactivity and prolong its therapeutic effects. Delivery vehicles for angiogenic factors can 
be developed from natural or synthetic materials. Many natural materials have good 
biocompatibility and degradability; however, they suffer from source and batch variations 
that often lead to different biological properties. In addition, large-scale production of 
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natural materials is challenging. On the other hand, synthetic materials usually offer better 
quality control. In view of this, the biomaterials field has sufficiently advanced to design 
biocompatible and biodegradable materials with cell and tissue specificity.  
The recent development of a new family of amino acid-based biodegradable poly(ester 
amide)s (PEAs) that are susceptible to either hydrolytic or enzymatic degradation provides 
additional resources to fabricate new biodegradable fibers with varying degradation rates 
for potential biomedical applications, such as drug delivery and vascular tissue engineering 
[7]. The by-products following degradation of these PEAs will include amino acids, which 
are found physiologically, limiting their potential systemic toxicity [8, 9]. Moreover, their 
degradation mechanism  is governed by surface erosion [10], which limits the localized 
accumulation of degradation by-products, supporting cell attachment and proliferation. 
Unlike  polyesters [11], PEA degradation is accompanied by the release of less acidic by-
products compared to polyesters, thus avoiding significant pH decrease in the vicinity of 
the scaffold usually resulting in inflammatory responses. Furthermore, surface eroding 
PEA scaffolds exhibit linear drug release kinetics, which provides better control of the drug 
release profile. PEAs successfully synthesized in our laboratory were found to have the 
potential to promote vascular tissue regeneration owing to their biomimetic properties and 
favorable degradation profiles [8, 10]. Multiple growth factors can be loaded into PEA 
delivery vehicles, potentially sustaining their release, enhancing their efficacy and 
accelerating favorable cell-material interactions. In this work, PEA was used to fabricate 
biodegradable electrospun fibers for dual and controlled delivery of angiogenic and 
arteriogenic growth factors to support mature and functional neovessel formation.  
 
 Hypothesis and Objectives 
1.2.1 Hypothesis 
It is hypothesized that dual and controlled delivery of angiogenic and arteriogenic factors 
from biodegradable electrospun PEA fibers promotes the assembly of stable and functional 
neovasculature. 
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1.2.2 Objectives  
 
In order to test the above hypothesis, the following objectives were formulated: 
• Fabrication and optimization of PEA electrospun fibers, to obtain bead-free nanofibers 
with uniform fiber diameter distribution and loading a model protein (bovine serum 
albumin; BSA) and the target protein (fibroblast growth factor-9; FGF9). 
• Dual loading of the PEA electrospun fibers with fibroblast growth factor-2 (FGF2) and 
FGF9, and characterization of the delivery system in terms of morphological properties, in 
vitro release kinetics, and bioactivity of the released growth factors. 
• In vitro study of the effect of the growth factor-loaded PEA electrospun fibrous scaffold 
on cell viability and proliferation using NIH-3T3 fibroblasts, 10T1/2 cells, and human 
coronary artery smooth muscle cells (HCASMCs), inflammatory host response using 
human monocytic cell line (THP-1), directed smooth muscle cell migration and endothelial 
cell tube formation. 
• In vivo angiogenesis evaluation of the developed PEA delivery system using an ex ovo 
chick chorioallantoic membrane (CAM) model and ischemic hindlimb mouse model. 
 
  Thesis Outline 
 
This thesis is divided into six chapters. A brief introduction about the clinical motivation 
of this research (ischemic vascular disease) and the need for new treatment approaches 
such as therapeutic angiogenesis, together with the hypothesis and objectives are 
introduced in Chapter 1. A broad literature review of recent advances in growth factor 
delivery for therapeutic angiogenesis is presented in Chapter 2. The main research findings 
are presented in Chapters 3-5. Chapter 3 reports the fabrication and optimization of PEA 
electrospun fibers and loading them with a model protein (BSA) and FGF9 using either 
blend or emulsion electrospinning technique and their characterization in terms of 
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morphological properties, in vitro release kinetics, and bioactivity of the released growth 
factor. Chapter 4 discusses dual loading of the PEA electrospun fibers with FGF9 and 
FGF2 using a mixed blend and emulsion electrospinning technique, in vitro angiogenesis 
assays and evaluating the inflammatory host response using THP-1 human monocytes. 
Chapter 5 focuses on the in vivo angiogenesis evaluation of the FGF-loaded PEA fibers 
using ex ovo chick choriallantoic membrane model and ischemic hindlimb mouse model. 
Finally, a general discussion with conclusions outlining the strengths, limitations and 
future directions are presented in Chapter 6. 
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Chapter 2  
2 Literature Review: Advances in Growth Factor Delivery for 
Therapeutic Angiogenesis 
Overview: This chapter provides background information on natural blood vessel 
formation, signaling molecules involved in the angiogenesis process, angiogenic growth 
factor delivery; highlighting the benefits of their controlled delivery and spatiotemporal 
presentation, and lastly discussing safety concerns of the angiogenic growth factor 
delivery. 
 
 Abstract 
Therapeutic angiogenesis is a new revascularization strategy to induce new vessel 
formation. The biology and delivery of angiogenic growth factors involved in vessel 
formation have been extensively studied but success in translating the angiogenic capacity 
of growth factors into benefits for vascular disease patients is still limited. This could be 
attributed to issues related to patient selection, growth factor delivery methods or lack of 
vessel maturation. Comprehensive understanding of the cellular and molecular cross-talk 
during the different stages of vascular development is needed for the design of efficient 
therapeutic strategies. The presentation of angiogenic factors either in series or in parallel 
using a strategy that mimics physiological events, such as concentration and spatio-
temporal profiles, is an immediate requirement for functional blood vessel formation. This 
review provides an overview of the recent delivery strategies of angiogenic factors, and 
discusses targeting neovascular maturation as a promising approach to induce stable and 
functional vessels for therapeutic angiogenesis. 
Key words: Growth factors; Neovascular maturation; Therapeutic angiogenesis. 
                                                 
*
 A version of this chapter is published as a review article “Somiraa S. Said, J. Geoffrey Pickering and 
Kibret Mequanint, Journal of Vascular Research (2013), 50; 35-51”. Adapted with permission from 
KARGER Publishers © 2012. 
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 Introduction 
Notwithstanding rapid advances made in treatment options, cardiovascular diseases 
remained the leading cause of death in developed countries [1] . In 2008, ischemic heart 
disease accounted for 7.3 million deaths worldwide [2]. The primary cause of ischemic 
heart disease is atherosclerosis - a thickening of the lining of the coronary arteries, and the 
subsequent myocardial ischemia - resulting in functional deficits and infarction. Although 
considerable progress has been made in preventing and treating atherosclerotic vascular 
disease (such as thrombolysis, angioplasty, stenting, and surgical bypass), there is no better 
clinical alternative to the patient's own blood vessels when a coronary artery must be 
bypassed. However, autologous vein and artery grafts cannot always be used either due to 
damage, pre-existing disease, or distal coronary arteries that are unsuitable for surgical 
anastomosis. On the other hand, synthetic grafts can result in immunologic and thrombotic 
complications [3]. Consequently, nearly 7% of ischemic heart disease patients become 
ineligible for standard revascularization techniques such as angioplasty or bypass surgery 
[4]. In these patients, the challenge to improve blood flow to the ischemic heart has led to 
extensive research and numerous innovative approaches in the field of vascular 
regenerative medicine [5]. One of the novel strategies in vascular regenerative medicine is 
therapeutic angiogenesis, which can include the administration of growth factors to induce 
new vessel formation. This technique has been shown to promote myocardial healing after 
an infarct in animals demonstrating the functional importance of augmenting the coronary 
circulation [6, 7]. This, in turn, accelerates the potential of therapeutic angiogenesis as a 
treatment modality to patients with advanced symptomatic ischemic heart disease, who are 
ineligible to receive standard invasive revascularization strategies [8, 9]. In this review, an 
overview of the biology of angiogenesis is provided along with the discussion of the basic 
characteristics of angiogenic factors, different delivery technologies, and neovascular 
maturation to form stable and functional vessels through therapeutic angiogenesis 
strategies.  
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 Blood Vessel Formation: Vasculogenesis, Angiogenesis and 
Arteriogenesis  
Coronary vasculogenesis, arteriogenesis, and angiogenesis are a spectrum of processes that 
lead to vessel formation [10]. Vasculogenesis is the de novo formation of blood vessels in 
the embryo from angioblasts or endothelial progenitor cells that migrate, proliferate, and 
differentiate to form endothelial cells (ECs), and subsequently organize into cord-like 
structures [11, 12]. It involves  both cell-cell and cell-extracellular matrix (ECM) 
interactions directed spatially and temporally by growth factors [13]. This dynamic process 
has also been recently suggested to occur in adulthood, where circulating endothelial 
progenitor cells are recruited to ischemic sites [14]. Arteriolar networks are often 
remodeled postnatally by the maturation of pre-existing collaterals in response to metabolic 
demands through the process of arteriogenesis [15]. Angiogenesis, on the other hand, is the 
process of blood vessel sprouting from pre-existing vasculature and includes subsequent 
remodeling steps such as pruning, vessel enlargement, and intussusceptions to form stable 
vessel networks [16, 17]. Angiogenesis is a beneficial process occurring naturally during 
wound healing, the female monthly reproductive cycle, and pregnancy. Alternatively, 
angiogenesis can occur as a part of a diseased body where it can aid in cases of ischemia 
or lead to a disease in the promotion of tumors [18]. During normal function, the body 
controls the growth of blood vessels using pro-angiogenic factors to stimulate and anti-
angiogenic factors to negatively regulate this phenomenon. The events of the angiogenesis 
process occur in an orderly series (Figure 2-1). It starts by the release of angiogenic growth 
factors from the ischemic tissues, diffusing into the nearby tissues. The angiogenic growth 
factors then bind to specific receptors located on the ECs of nearby pre-existing blood 
vessels. Once growth factors bind to their receptors, the ECs become activated, sending 
signals from the cells' surface to the nucleus. The EC machinery begins to produce new 
molecules including enzymes that degrade the basement membrane surrounding existing 
vessels.  ECs begin to proliferate and migrate out and integrins facilitate sprouting of the 
new blood vessel forward. Additionally matrix metalloproteinases are produced to degrade 
the ECM in the direction of the sprouting vessel tip in order to accommodate it. As the new 
vessel extends, the tissue is remodeled around the vessel. Subsequent to this, sprouting ECs 
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roll up to form a tube. Individual tubes connect to form blood vessels that can circulate 
blood. Newly formed blood vessel tubes are stabilized by specialized perivascular cells, 
referred to as mural cells, which can be either vascular smooth muscle cells (VSMCs) or 
pericytes. Pericytes are thought to stabilize capillaries, whereas VSMCs are critical for the 
control of vessel conductance which is required for the restoration of blood flow [18]. With 
continuing flow as well as increasing shear stress and blood pressure over time during 
vascular development, greater vessel stability is required. Such vessel stability is attained 
through EC-mural cell interactions and concomitant ECM remodeling including deposition 
and cross-linking of ECM components (i.e., basement membranes, interstitial matrices, and 
elastin-rich matrices) at distinct places in the vessel wall [19, 20].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1: Major events of the angiogenesis process.  
(A) Angiogenic factor production and release to the surrounding tissue. (B) Paracrine 
signalling via angiogenic factor-EC receptor binding. (C) Endothelial cell directional 
migration and tube elongation. (D) Nascent vessel branching. (E) Neovascular maturation 
and investment of perivascular cells. Modified from the Angiogenesis foundation website 
[18]. 
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In view of the above, the goal of therapeutic angiogenesis is to enhance the natural process 
of ischemic revascularization through delivery of angiogenic factors, and to increase blood 
vessel density and tissue function [3]. Understanding the molecular mechanisms of 
vascular maturation is essential in developing competent neovascularization strategies. For 
such complicated developmental process, multiple angiogenic factors are required that act 
synchronically to form the correct patterning found within a functional blood vessel [3]. 
 
 Angiogenic Growth Factors 
Ischemia resulting from an arterial occlusion is a natural stimulus for endogenous 
angiogenesis which induces upregulation of angiogenic growth factors and mobilization of 
circulating cellular elements collectively enabling the development of an accessory 
vasculature [5, 21]. In the sections that follow, major angiogenic growth factors are 
outlined whereas additional factors are listed in Table 2-1. 
Table 2-1: Selected signaling molecules involved in angiogenesis process [22]. 
Signaling molecule Function(s) 
Vascular endothelial growth 
factors 
Involved in angiogenesis and lymphangiogenesis, act 
specifically on ECs to induce their migration, proliferation, 
formation of new blood vessels,  and induce vascular 
permeability 
Fibroblast growth factors 
Involved in angiogenesis, EC proliferation, cord and lumen 
formation, recruitment of inflammatory cells, pericytes and 
VSMCs, and vessel maturation 
Platelet-derived growth 
factors 
Promote vascular maturation by recruiting VSMCs and 
pericytes to newly formed vessels, induce inflammatory cell 
chemotaxis, recruit stem cells from bone marrow, and  
responsible for the migration of SMC and formation of the 
neointima 
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Angiopoietin-1 
EC chemotaxis, prevention of excessive vascular 
permeability, formation of cords and lumens, and vessel 
stabilization via EC-mural cells interactions 
Angiopoietin-2 
Vessel destabilization, detachment of VSMCs, and 
degradation of ECM 
Nitric oxide 
Vasodilatation, co-factor for VEGFs, FGFs and other 
angiogenic factors 
Granulocyte colony-
stimulating 
factor 
Mobilization of bone marrow–derived stem cells, induces 
proliferation and enhance survival of cardiomyocytes by direct 
effects on cardiomyocytes, or by the release of proangiogenic 
mediators 
Hypoxia-inducible factor 1a 
Upregulation of several genes to promote survival in low-
oxygen conditions. These include glycolysis enzymes, which 
allow ATP synthesis in an oxygen-independent manner, and 
VEGF, which promotes angiogenesis 
Hepatocyte growth factor 
It is secreted by mesenchymal cells and acts as a multi-
functional cytokine on cells of mainly epithelial origin. Its 
ability to stimulate mitogenesis, cell motility, and matrix 
invasion gives it a chief role in angiogenesis and tissue 
regeneration 
Insulin-like growth factor 
A key regulator of cellular proliferation and differentiation, 
promotes physiological cardiac growth, reduces apoptosis and 
collagen deposition, enhances angiogenesis, and improves 
cardiac function 
 
2.4.1 Vascular Endothelial Growth Factor (VEGF) Family  
Among the many factors implicated in angiogenesis, VEGF is one of the most investigated 
families of angiogenic growth factors. The VEGF family includes VEGF-A, -B, -C, -D, -
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E, -F and placental growth factor (PlGF). VEGF-A is mainly involved in angiogenesis 
while VEGF-C and VEGF-D are involved in lymphangiogenesis. The human VEGF-A 
gene is organized into eight exons and alternative exon splicing results in 5 different 
isoforms (VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206) [23-25]. VEGF165 is the 
most predominant isoform as well as the most potent in terms of stimulating angiogenesis 
[3]. VEGF ligands mediate their angiogenic effects by binding to specific VEGF receptors, 
leading to receptor dimerization and downstream signal transduction. VEGF receptor 
signalling is detailed elsewhere and the reader is referred to excellent reviews on this 
subject [26, 27]. VEGF ligands bind to 3 primary receptors (VEGFR-1, VEGFR-2 and 
VEGFR-3) and 2 co-receptors (neuropilin receptors NP-1 and NP-2). Of the primary 
receptors, VEGFR-1 and VEGFR-2 are mainly associated with angiogenesis [28]. The 
third primary receptor, VEGFR-3, is associated with lymphangiogenesis. Endothelial 
expression of VEGF receptors varies among the 3 primary receptors; VEGFR-2 is 
expressed on almost all ECs, while VEGFR-1 and -3 are selectively expressed in distinct 
vascular beds [5]. VEGF acts specifically on ECs to induce their migration, proliferation, 
and formation of new or large vessels [3]. It also can act in an autocrine manner and 
increases vascular permeability. VEGF induces vascular permeability, vasodilatation, and 
upregulates expression of serinoproteases and interstitial collagenases, thereby promoting 
ECM degradation [29, 30]. VEGF production and subsequent angiogenesis can be 
triggered by a number of factors in the cellular microenvironment including but not limited 
to hypoxia, oncogenes, tumor suppressor genes, inflammatory cytokines, and other growth 
factors [31]. For example, acute myocardial infarction rapidly produces a prolonged over-
expression of VEGF and its receptors [32]. Moreover, it has been documented that VEGF 
increases the number of circulating endothelial progenitor cells in humans after VEGF gene 
therapy [33]. 
 
2.4.2 Fibroblast growth factor (FGF) family 
FGFs are another large family of growth factors directly involved in angiogenesis [34]. 
FGFs are pleiotropic factors that can stimulate and act on different cell types, including 
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vascular ECs. The FGF gene family is composed of 22 members that bind to seven FGF 
receptor  isoforms (FGFR1b, FGFR1c, FGFR2b, FGFR2c, FGFR3b, FGFR3c and FGFR4) [35]. 
The bulk of angiogenic experimental data is focused on FGF-1 (acidic, aFGF) and FGF-2 
(basic, bFGF) both of which are potent EC mitogens that also serve as ligands for other 
cell types, including VSMCs and fibroblasts. FGF binding induces receptor tyrosine kinase 
(RTK) dimerization, which leads  to the activation of signalling pathways involved in cell 
growth, differentiation, tissue maintenance, and wound repair [35]. FGF induces 
neovascularisation in vivo and is implicated in the growth of new blood vessels during 
wound healing and embryogenesis. In vitro, FGF induces cell proliferation, migration, and 
production of proteases in ECs by interacting with specific co-receptor systems consisting 
of tyrosine kinase FGF receptors (FGFRs) and heparin-like glycosaminoglycans (HLGAG) 
[5, 36]. It has been reported that FGFs act through autocrine, intracrine or paracrine 
mechanisms to induce angiogenesis in vascular lesions [37]. Although intimate cross-talk 
takes place between the FGF-2 and VEGF signalling pathways often activating one another 
to promote angiogenesis, these growth factors, however, have distinct biological effects on 
ECs [3, 37]. 
 
2.4.3 Platelet-derived Growth Factor (PDGF)  
PDGF is a pluripotent angiogenic growth factor synthesized by many different cell types 
in response to external stimuli such as hypoxia or growth factor stimulation, and it has a 
broad expression pattern [3]. PDGF, together with other growth factors, such as VEGF and 
FGF, promotes vascular maturation by recruiting VSMCs and pericytes to newly formed 
vessels [38, 39]. In addition, PDGF mediates collagen production by fibroblasts, regulates 
lymphatic growth, induces inflammatory cell chemotaxis and recruits stem cells from bone 
marrow [40].  
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2.4.4 Other Angiogenic Stimulators 
The presence of inflammatory cells like macrophages, monocytes and neutrophils triggers 
an angiogenic response [29]. In addition to the angiogenic factors discussed in the 
preceding sections, several other growth factors that impact angiogenesis such as 
angiopoietins (Ang-1 and Ang-2), monocyte chemotactic protein-1 (MCP-1), granulocyte 
macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), leptin, 
transforming growth factors (TGF-α and TGF-β), tumour necrosis factor alpha (TNF-α), 
and brain-derived neurotrophic factor (BDNF) have been identified [5]. Furthermore non-
peptide molecules, such as nitric oxide (NO), prostaglandins, adenosine and hyaluronic 
acid have been also reported to have pro-angiogenic properties [29]. However, clinical 
trials have focused mostly on members of the VEGF and FGF families [6, 8]. Table 2-1 
summarizes the role of selected signalling molecules involved in the angiogenic process. 
  
 Angiogenic Growth Factor Delivery 
2.5.1 Protein versus Gene Therapy 
Therapeutic angiogenesis regimens have focused on the administration of a single growth 
factor, in spite of the complexity of the angiogegenesis process, with VEGF-A and FGF 1 
and 2 being the most extensively studied angiogenic factors [22]. Growth factor proteins 
can be administered either directly or via gene-based approaches, employing naked 
plasmid DNA or a viral vector that encodes the gene to be incorporated by the host ECs 
[22]. Obvious advantages of gene therapy strategy include longer-term expression of an 
angiogenic gene and targeting a specific tissue. However, the local concentration of the 
angiogenic protein is highly dependent on the level of expression of its gene, which is 
difficult to regulate [41]. Safety concerns usually exist regarding the exposure of patients 
to foreign genetic material and viral vectors. As well, the effectiveness of gene transfection 
methods can be compromised by preformed antibodies and inflammatory responses, and 
the probability of inactivation could increase with re-administration. Protein therapy may 
arguably be more applicable for clinical use than gene therapy, due to the more predictable 
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initial dosing of the angiogenic factor, pharmacokinetics and tissue therapeutic levels. 
Additionally, the use of controlled-release delivery systems can provide prolonged 
exposure, compensate for the short biological half-life of the angiogenic growth factors, 
and avoid potential adverse effects of the high plasma concentrations, which is required for 
adequate myocardial uptake [22]. However, recombinant proteins can be difficult and 
expensive to produce and may require complicated delivery technologies. 
 
2.5.2 Gene Transfer in Therapeutic Angiogenesis 
Early studies of gene therapy utilized plasmid DNA owing to its safety and ease of 
production. Despite the promising results of VEGF encoding plasmid DNA and other 
angiogenic factors in preclinical trials and small clinical trials [42, 43], large randomized 
controlled trials did not support the use of plasmid DNA, due to its low transduction 
efficacy, lack of a dose response effect, and its transient expression [44, 45]. Although, 
plasmid DNA is considered safe, it can result in transient fever, inflammation, and 
sometimes myocardial infarction [44, 46].  Adenovirus (Ad) vectors have demonstrated 
high transduction efficacy, and more specifically, they are much more efficient than 
plasmid DNA in the myocardium [47]. Retroviruses were the first vectors to be used for in 
vivo cardiovascular gene transfer, but safety concerns led to reduced interest in them [48]. 
As an alternative strategy, lentiviruses have been recently used in cardiovascular gene 
therapy, for the treatment of familial hypercholesterolemia [49], whereas sendai viruses 
[50] and herpesviruses [51] have also been utilized in some cardiovascular gene therapy 
applications. Finally, baculoviruses were found to transduce blood vessels transiently with 
a moderate efficiency [52]. Despite this encouraging data, their advantage is not clear as 
macrophage-specific immunostaining detected signs of inflammation comparable to 
adenoviruses. 
Adeno-associated virus (AAV) vectors are attractive candidates for cardiovascular gene 
therapy having a natural tropism towards VSMCs, cardiomyocytes and skeletal muscles. 
AAV transduces quiescent cells, and drives long-term gene expression lasting several 
months. It generates only a restricted inflammatory reaction, and the wild-type virus is not 
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known to cause any diseases in humans [53]. AAV has a long-lasting gene expression 
pattern with lower maximal gene expression levels than those induced by Ads [54]. Most 
importantly, the peak expression of AAVs can be achieved in just a few days after the 
transduction [55].  
 
 Preclinical Studies 
2.6.1 In vivo Studies with Vascular Endothelial Growth Factor 
Animal studies with VEGF have mainly involved VEGF165 and VEGF121 isoforms. There 
have been successful results in myocardial ischemia models [56-59]. In one study, the 
implantation of collagen membrane patch loaded with collagen-binding domain fused to 
VEGF into infarcted rabbit myocardium, effectively improved left ventricle cardiac 
function and increased vascular density compared to control group [57]. In a rat model of 
a resected right ventricular free wall and replaced with the VEGF-immobilized collagen 
scaffold, Miyagi et al. [58] reported that covalently immobilized VEGF-collagen scaffolds 
improved tissue formation, increased blood vessel density and reduced construct thinning. 
Controlled delivery of VEGF165 from poly(lactic-co-glycolic acid) (PLGA) microparticles 
in a rat model of myocardial ischemia-reperfusion, resulted in enhanced angiogenesis and 
arteriogenesis after one month of the treatment [56]. Sustained and localized delivery of 
VEGF together with insulin-like growth factor-1 from biodegradable gelatin microspheres 
was proved to attenuate post-myocardial infarction remodeling in a rat model of 
experimental heart failure [59]. Also, gene transfer of adenoviral VEGF-A165 and the 
mature form of VEGF-D, injected intramyocardially into pigs via a catheter-mediated 
approach, resulted in transmural angiogenesis induction in porcine heart [60]. 
 
2.6.2 In vivo Studies with Fibroblast Growth Factor 
FGF-1 and FGF-2 have been the most studied of the FGF family. FGF-1 plays a pivotal 
role in the spontaneous formation of collaterals as it is strongly expressed in ischemic 
myocardium [22, 61]. Large animal studies using FGF-1 to stimulate angiogenesis initially 
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produced disappointing results, which can be argued by the short biological half-life (15 
minutes at 37°C) of the FGF-1 [62]. Intramyocardial sustained delivery of FGF-
2−impregnated gelatin hydrogel microspheres was demonstrated to enhance angiogenesis 
and ventricular function in a rat myocardial infarcted heart model [63]. Improved 
myocardial perfusion and cardiac function by controlled-release of FGF-2 using fibrin 
glue, was reported in a canine acute infarct model - induced by ligation of the left anterior 
descending coronary artery - with dramatic increase of the total vascular density in 
comparison with the control group that underwent coronary artery ligation without 
treatment  [64]. In another study, heart failure due to myocardial infarction was induced in 
pigs followed by intramyocardial administration of biodegradable gelatin microspheres 
loaded with bFGF 4 weeks after infarction, which resulted in improved left ventricular 
(LV) function and inhibited LV remodeling compared to the control group [65]. In a 
preclinical study using a pig model of myocardial ischemia, a single intracoronary infusion 
of adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4), improved cardiac contractile 
function and regional blood flow in the ischemic region during stress [66]. 
 
 Clinical Trials in Ischemic Heart Disease 
After preclinical studies had established a proof of concept for therapeutic angiogenesis, 
investigators sought to extrapolate these findings to patients with myocardial ischemia. 
Patients included in the clinical trials of therapeutic myocardial angiogenesis, suffered 
from severe angina unresponsive to medical therapy and were unsuitable for standard 
revascularization techniques [5]. Major therapeutic angiogenesis clinical trials for 
myocardial ischemia using protein/gene therapy are summarised in Table 2-2. 
Most of these clinical trials showed little success in translating the angiogenic capacity of 
growth factors into benefits to ischemic heart disease patients either through gene or protein 
therapy. The potential reasons for such poor results include the limited duration of the 
therapy achieved with bolus delivery of recombinant proteins or gene delivery vectors, the 
high costs associated with protein therapy because of the need for large doses and 
complicated delivery technologies, issues with patient selection, and the generation of 
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immature and unstable blood vessels that regress over time. Potential strategies to 
overcome these challenges include the use of controlled delivery systems that allow 
prolonged angiogenic stimulation and the use of growth factor combinations to stimulate 
the generation of mature and stable blood vessels. Ultimately, the key is acquiring a 
neovasculature that can effectively deliver flow via vasoresponsiveness - the dynamic 
regulation of the luminal diameter of arterioles, which is crucial for controlling the 
metabolic needs of the tissues. 
Table 2-2: Major randomized myocardial angiogenesis clinical trials using 
protein/gene therapy. 
Growth factor Route and dose n Results Reference 
Granulocyte-
macrophage 
colony 
stimulating 
factor   (GM-
CSF) 
40 µg intracoronary 
(IC) once and 10 
µg/kg subcutaneous 
(SC) for 2 weeks 
21 Short-term administration protocol of 
GM-CSF showed significant 
improvement of collateral flow index 
(p < 0.05) and ECG signs (p = 0.04) 
after vascular balloon occlusion. 
Seiler et al. 
[67] 
GM-CSF 10 µg/kg SC for 2 
weeks 
14 Subcutaneous short-term protocol of 
GM-CSF significantly promotes 
coronary collateral artery growth 
among patients with CAD. However, 
two cases of acute coronary 
syndromes in the treatment group 
were reported.  
Zbinden et 
al. [68]  
Granulocyte 
colony 
stimulating 
factor   (G-
CSF) 
10 µg/kg SC for 5 d 
after percutaneous 
coronary intervention 
(PCI) for acute 
myocardial infarction 
(AMI) 
114 Stem cell mobilization by G-CSF 
therapy in patients with acute 
myocardial infarction had no 
significant influence on infarct size, 
left ventricular function, or coronary 
restenosis. 
Zohlnhofer 
et al. [69] 
 19 
  
G-CSF 10 µg/kg SC for 6 
days after PCI for 
AMI 
78 Bone marrow stem cell mobilization 
with subcutaneous G-CSF did not 
lead to significant improvement in 
ventricular function after acute 
myocardial infarction. 
Ripa et al. 
[70] 
FGF-2 10 or 100 µg 
delivered via 
sustained-release 
heparin-alginate 
microcapsules 
implanted in 
ischemic  myocardial 
territories during 
coronary artery 
bypass graft (CABG) 
24 Magnetic resonance assessment of the 
target ischemic zone showed 
significant improvement of 
myocardial perfusion and reduction in 
the target ischemic area in the 100 µg 
bFGF group, 3 months after CABG. 
Laham et al. 
[71] 
Recombinant 
FGF-2 
0, 0.3, 3, 30 µg/kg IC 337 A single IC infusion of rFGF-2 
showed no significant difference of 
exercise tolerance or myocardial 
perfusion.  But does show trends 
toward symptomatic improvement at 
90 days but not at 180 days due to the 
continued improvement in the 
placebo group. 
Simons et al. 
[72] 
Adenovirus5F
GF-4 
(Ad5FGF-5) 
5 ascending doses IC 79 A trend towards clinical improvement 
in exercise treadmill testing. Single 
intracoronary administration of Ad5-
FGF4 was safe and well tolerated 
with no immediate adverse events. 
Grines et al. 
[73] 
Recombinant 
VEGF-A165 
17 ng/kg/min IC and 
intravenous (IV) or 
178 rhVEGF offered no improvement 
beyond placebo in all measurements 
Henry et al. 
[74] 
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50 ng/kg/min IC and 
IV 
by Day 60. High-dose rhVEGF 
resulted in significant improvement in 
angina class and non-significant 
improvement in exercise tolerance 
time and angina frequency at 120 
days compared to placebo. 
AdVEGF165 or 
naked plasmid  
(2 × 1010 pfu or 2 mg 
DNA) IC during 
percutaneous 
transluminal 
coronary angioplasty 
103 Significant improvement of 
myocardial perfusion in the 
adenoviral VEGF group at 6 months. 
No difference in vessel restenosis 
rates. 
Hedman et 
al. [44]  
AdVEGF121 2 × 10
10 pfu 
intramyocardial 
injection via mini-
thoracotomy 
67 Improvement in exercise-induced 
ischemia at 26 weeks. 
Stewart et al. 
[75]  
Naked 
VEGF165 
plasmid 
0.5 mg percutaneous 
intramyocardial 
injection 
80 No significant improvement of stress-
induced myocardial perfusion. 
However, regional wall motion was 
significantly improved. 
Kastrup et al. 
[45]  
Plasmid 
VEGF165 
2.0 mg 
intramyocardial 
injection 
93 No improvement in myocardial 
perfusion; significant reduction in the 
ischemic area, increase in exercise 
test time and improvement in angina 
class. 
Stewart et al. 
[76]  
AdGV-
VEGF121 
intramyocardial 
injection 
17 No significant difference in 
myocardial perfusion and exercise 
capacity at 52 weeks. Premature study 
termination. 
Kastrup et al. 
[77]  
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 Targeting Neovascular Maturation 
2.8.1 Cues for Functional Blood Vessel Formation  
Pericyte and VSMC recruitment to nascent vessels is pivotal for vessel maturation [78]. 
Absence of perivascular cell coverage subjects newly formed vessels to regression and they 
become dependent upon ongoing growth factor stimulation from the environment for their 
survival [79]. However, nascent vessels are stabilized and become resistant to regression 
once they are invested with pericytes. Basement membrane matrices are one of the key 
ECM components facilitating EC tube stabilization. They are in direct contact with the ECs 
layer on its abluminal surface and provide important signals that control the stability of this 
layer. Despite the substantial information which exists on the signalling properties of 
basement membrane components toward different cell types, much remains to be learned 
concerning how such components affect EC behaviour at distinct stages of vascular 
morphogenesis and stabilization in embryonic and postnatal life [80]. The importance of 
pericyte recruitment to EC-lined tubes in vitro and in vivo, has been demonstrated to be 
essential to stimulate vascular basement membrane matrix assembly, which is considered 
a key step in vascular maturation and stabilization [81]. Not surprisingly, stimulation of 
cell migration for vascular maturation is growth factor dependent. This is exemplified by 
Regranex®, a genetically engineered PDGF based commercial product developed for the 
recruitment of cells in wound healing [82]. Although its reported mechanism of action is 
through mesenchymal cell proliferation and matrix production, there is a probability that 
part of PDGF’s mechanism of action in chronic wound healing may also be due to 
improvement of neovascular maturation [83].  
The endothelial basement membrane is unique in its accumulation of the protein von 
Willebrand Factor (vWF), which is derived from endothelial Weibel-Palade body 
secretions [84]. Following the formation of a quiescent vasculature, vWF plays an essential 
role in haemostasis. In addition to its role in the recruitment, adhesion, and migration of 
leukocytes, vWF has been recently shown to play a role in vessel patterning [85]. Although 
multiple cell types, secreted proteins, and growth factors collectively and in coordination 
regulate angiogenesis and vessel stabilization, the Notch signalling pathway is unique in 
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its involvement in multiple stages of angiogenesis, from initial vascular plexus formation 
and patterning, to VSMC recruitment and vascular remodeling  [86]. Scheppke et al. [86] 
reported that VSMC recognition of the Notch ligand (Jagged1) on ECs leads to expression 
of integrin αvβ3 on VSMCs. Once expressed, integrin αvβ3 facilitates VSMC adhesion to 
vWF in the endothelial basement membrane of developing retinal arteries, leading to vessel 
maturation. Their conclusions were based on the notion that genetic or pharmacological 
disruption of Jagged1, Notch, αvβ3, or vWF suppresses VSMC coverage of nascent vessels 
and arterial maturation during vascular development [86]. 
 
2.8.2 Co-delivery of Ang-1, PDGF-BB, or HGF with VEGF and FGF-2 for 
Vascular Stabilization 
Given the lack of clear benefits of VEGF gene therapy in two major clinical trials [45, 76], 
targeting neovascular maturation is an attractive alternative or supplementary strategy to 
ensure efficient therapeutic angiogenesis. Although, VEGF directly stimulates EC 
proliferation and migration, it has been reported that it can act as an inhibitor of 
neovascularization on the basis of its capacity to disrupt VSMC function [87]. Specifically, 
under conditions of PDGF-mediated angiogenesis, VEGF ablates pericyte coverage of 
nascent vascular sprouts, leading to vessel destabilization [87]. Perivascular nascent vessel 
maturation process is a natural feature of blood vessel development in the embryo [88]; 
however, there are no strategies for promoting an equivalent vascular maturation process 
in ischemic adult tissues. Such strategies could also be important to the viability of tissue-
engineered substitutes, which can be compromised by inefficient vascularization and 
oxygen delivery [89]. Evidently, the formation of a mature vasculature requires precise 
spatial and temporal regulation of a large number of angiogenic stimulators and inhibitors. 
The complexity and heterogeneity of the factors involved in vascular maturation suggest 
the use of a co-delivery or sequential delivery approach, to overcome the drawbacks of 
single growth factor delivery. For example, systemic co-administration of Ang-1 and 
VEGF through intravenous adenoviral delivery has been shown to protect adult vasculature 
from lethal vascular leakage induced by systemic VEGF expression [90]. Local co-
expression of VEGF and Ang-1 has been reported to reduce VEGF-induced leakage in rat 
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hind limb ischemia [91]. Temporally separated delivery of VEGF and Ang-1 gene therapy 
also resulted in sustained and functional neovascularization in unilateral hind limb 
ischemia rat model [92]. Moreover, adenoviral delivery of VEGF and Ang-1 induced 
vessels that were more mature and persisted after 4 weeks compared to VEGF alone [93]. 
Adeno-associated viral vectors expressing cardiac-specific and hypoxia-inducible VEGF 
[AAV-myosin light chain-2v (MLC)VEGF] and Ang1 (AAV-MLCAng1) were co-injected 
in a porcine myocardial infarcted  heart model [94]. Cardiac–specific and hypoxia–induced 
co-expression of VEGF and Ang1 was found to improve the perfusion and function of 
porcine myocardial infarcted heart through the induction of angiogenesis and 
cardiomyocyte proliferation [94]. 
Similarly the approach of co-delivering PDGF-BB with VEGF is justified by the 
suggestion that increasing the recruitment of pericytes could provide a comprehensive 
stimulation of several pathways in a co-ordinated fashion, and hence better simulation of 
the physiological process. Delivery of recombinant VEGF and PDGF-BB proteins from a 
PLGA scaffold has been shown to induce larger and more mature vessels compared with 
VEGF alone subcutaneously and in ischemic skeletal muscle [95]. The combination of 
recombinant PDGF-BB with FGF-2 has been reported to increase vascular stabilization in 
the mouse cornea and in rat and rabbit hind limb ischemia models [38]. However, the co-
delivery of PDGF-BB was found not to correct VEGF induced abnormalities in the cornea. 
Thus, it was not pursued further in the more clinically relevant muscular tissue. Co-delivery 
of the VEGF and PDGF-BB genes to ischemic myocardium by venous retroinfusion of 
adeno-associated viral vector has recently been found to significantly improve perfusion 
and collateral arteriogenesis [96]. It is worth mentioning that PDGF together with other 
factors, originating from the aggregating platelets, mononuclear cells, endothelial cells, and 
VSMCs themselves at the site of injury, act as a proliferating agent and are responsible for 
the migration of the VSMCs and the process of restenosis [97]. Given the beneficial effect 
of VEGF and PDGF co-delivery in prior studies [38, 95], the suggestion that PDGF causes 
restenosis requires further investigation. 
In addition to Ang-1 and PDGF-BB, co-delivery of HGF was reported to potently induce 
arteriogenesis and reduce cardiac fibrosis. Intramyocardial delivery of cross-linked 
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albumin-alginate microcapsules that sequentially release FGF-2 and HGF was investigated 
in a rat model with chronic heart failure induced by coronary ligation [98]. Data from the 
study indicated that dual delivery stimulated angiogenesis and prevented cardiac 
hypertrophy and fibrosis, leading to improved cardiac perfusion after 3 months. 
 
2.8.3 Acquiring Neovasculature Vasoresponsiveness 
Although stimulating angiogenesis using growth factors is an essential first step, it is not a 
sufficient condition for its efficiency. It has become recognized that angiogenic growth 
factors cannot generate vasoreactive neovessels by themselves [99]. Vasoreactivity is the 
dynamic regulation of the luminal diameter of arterioles and arteries and it is vital to 
controlling flow into capillary beds, and consequently, to meeting the oxygen and 
metabolic needs of tissues. Frontini et al. [99] reported that the delivery of fibroblast 
growth factor-9 (FGF-9) imparts stability, longevity and the ability to regulate blood flow 
through vasoresponsiveness of the newly formed microvessels. In this cited work, it was 
found that mural cell exposure to FGF-9 activated FGF receptor signalling, promoted cell 
elongation, decreased apoptosis, increased the expression of PDGFR and Sonic 
Hedgehog (SHH), and augmented the mural cell chemotactic response to PDGF-BB 
(Figure 2-2) . Unlike FGF-2, FGF-9 was found not to stimulate angiogenesis in 
subcutaneous implants, but instead it drives muscularization of angiogenic sprouts within 
the implant and enhances the ability of the microvasculature to receive flow and resist 
regression [99].  
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Figure 2-2: FGF9-mediated microvessel maturation. 
FGF9 stimulates mural cells to express Sonic Hedgehog, which signals the upregulation of 
PDGFR- in an autocrine manner. PDGF-BB, the ligand of this receptor, which is 
synthesized by the endothelial cell tubes, enhances the recruitment of FGF9-stimulated 
mural cells. Hence, the FGF9-SHH-PDGFR axis mediates the migration of mural cells to 
endothelial tubes resulting in microvessel maturation.    
 
 
Figure 2-3 illustrates FGF-9−stabilization of nascent microvessels through mural cell 
recruitment to ECs tubes. FGF-9 increases smooth muscle cell expression of the PDGF 
receptor, through the SHH pathway, thereby enhancing the recruitment of smooth muscles 
to nascent vessels. When FGF-9 was infused into ischemic mouse hind limb, the resulting 
microvessels were found to be invested with more VSMCs than those generated in the 
absence of FGF-9. In addition, FGF-9 injection had led to accelerated re-growth of muscle 
mass, along with improved limb function, compared to control vehicle [83]. 
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Figure 2-3: FGF9−stabilization of nascent microvessels through mural cells 
recruitment to endothelial cell tubes.  
Used with permission from Macmillan Publishers Ltd: [Nat Biotechnol][83]. 
 
 Angiogenic Growth Factors Delivery Technologies 
The use of recombinant protein growth factors may be a preferred therapeutic strategy 
compared with gene therapy [100]. Angiogenic growth factors have been delivered either 
by bolus injection or infusion into systemic circulation or the tissues of interest. The short 
half-life of these proteins results in low local availability that do not meet the spatial and 
temporal design criteria [17, 101-103]. One approach to overcome such limitations is the 
localized and sustained delivery of growth factors at the desired site from polymer-based 
delivery systems.  
 
2.9.1 Controlled Delivery of Angiogenic Factors from Polymer-based Systems 
Biodegradable polymer vehicles incorporating growth factors can provide sustained 
release into the site of interest yielding concentrations within the therapeutic range over a 
period of days to months [17, 104]. Moreover, polymer properties can be readily tailored 
to change the temporal and spatial release profiles, making polymer-based delivery systems 
promising candidates for therapeutic angiogenesis [17, 105-107]. Polymers used in 
controlled delivery of angiogenic factors include synthetic polymers such as poly(glycolic 
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acid) (PGA), poly(lactic acid) (PLA), and their copolymer (PLGA) [104, 108, 109]. In 
addition, natural polymers such as fibrin [110], collagen [111], alginate [112], chitosan 
[113], gelatin [114], and other hydrogels [115] can be used in the fabrication of controlled 
delivery systems. Delivery systems often comprise porous scaffolds, hydrogels or 
microspheres according to the desired application [105, 116]. The fabrication method used 
to produce the scaffold or vehicle can denature or inactivate the incorporated angiogenic 
factors.  Electrospinning together with gas-foaming techniques were reported to produce 
vehicles that retain the bioactivity of incorporated and released growth factors [117-120]. 
Fibrin gel has been used as delivery system of growth factors such as nerve growth factor 
[121], bFGF [122], VEGF [123], and transforming growth factor-beta [124]. Despite 
positive results, the release kinetics from such fibrin delivery matrix remained uncontrolled 
[3]. On the other hand, incorporation of thrombin and fibrinogen together with heparin in 
fibrin gels demonstrated better control of the release rate of heparin-binding growth factors, 
such as VEGF and FGF-2 [125], which can be explained by the fact that many angiogenic 
growth factors are found associated with heparin in native ECM. Moreover, photoreactive 
combinations of gelatin and heparin have also been employed to localize VEGF and FGF-
2 to polyurethane grafts [126]. Collagen and its derivative gelatin often have poor loading 
capacity for growth factors. Heparin has been covalently attached to collagen to enhance 
the capture of angiogenic growth factors in the matrix. The addition of glycosaminoglycans 
alters the cross-linking density of the matrix and decreases the pore size limiting the burst 
release of entrapped growth factors [3, 111].  Alginate microspheres can be employed for 
sustained release of entrapped proteins. Protein loss during bead preparation has been a 
major challenge for efficient drug delivery [3]. Microspheres of PLGA and poly(ethylene 
glycol) have been formulated for controlled release of VEGF with subsequent evaluation 
in vitro [104]. As with alginate microspheres, the exact processing parameters and 
subsequent retention of bioactivity remains challenging. VEGF has also been delivered 
from hydrocarbon stent coatings, which demonstrated increased EC growth [127]. 
Immobilization of growth factors has been adopted to induce specific and localized effect. 
It can protect against cellular inactivation and digestion [128]. Immobilized bFGF onto 
poly(ethylene glycol) diacrylate hydrogels has been reported to induce VSMC proliferation 
and migration [129].  
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2.9.2 Electrospun Fibers as Angiogenic Factor Delivery Vehicles  
Electrospinnning is an established technique for scaffold fabrication that can prolong the 
angiogenic factor release and overcome difficulties encountered with angiogenic factor 
incorporation within conventional scaffolds, such as controlling the release profile and 
retaining growth factor bioactivity. In the electrospinning process, a high voltage is applied 
to the droplet of polymer solution to overcome the surface tension and enable the formation 
of fibers with an average diameter ranging from the micrometer to the sub-micrometer 
range. Desirable release profiles can be achieved by controlling the chemical nature of 
polymers and bioactive molecules, size and morphology of fibers, porosity of fibrous 
structure and their degradation rate, and initial drug-loading [130]. An appropriately 
sustained growth factor release profile in combination with a nanofibrous scaffold could 
positively influence stem cell behavior and fate [119]. Sahoo et al. [119] reported that 
PLGA nanofibers incorporated with bFGF favored bone marrow stem cell attachment and 
subsequent proliferation. In this case, cells cultured on coaxial electrospun fibrous 
scaffolds demonstrated increased collagen production and upregulated gene expression of 
specific ECM proteins, indicating fibroblastic differentiation. Casper et al. [131] used a 
low molecular weight heparin (LMWH) grafted to poly (ethylene glycol) and electrospun 
this conjugate within PLGA for bFGF delivery. Heparin retention within the graft structure 
was increased as well as FGF retention with the conjugation versus LMWH alone. It has 
been proposed that the resulting nanoscale features, that are achievable with 
electrospinning, may be ideal for growth factor localization. Heparinized electrospun fibers 
were reported to efficiently bind bFGF, sustaining its release and preserving its bioactivity 
[120]. Chitosan/poly(vinyl alcohol) conjugated nerve growth factor scaffolds for potential 
neural tissue engineering purposes were prepared using electrospinning and reported to 
support cell attachment and proliferation [132]. Co-axial electrospun fibers offered both 
topographical and biochemical cues for regenerative medicine applications. The plasma 
factor VIII-releasing co-axial electrospun poly(urethane) fibers facilitated sustained 
treatment of hemophilia via a non-viral tissue engineering approach [118]. Emulsion 
electrospinning was adopted to embed bFGF into poly(ethylene glycol)-poly(DL-lactide) 
ultrafine fibers with a core-sheath structure to promote the wound healing process [133]. 
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Moreover, bFGF was physically immobilized within gelatin electrospun scaffolds with 
aligned or random fiber orientations. EC adhesion and orientation was found to be highly 
dependent on scaffold fiber orientation and morphology, where the cells expressed 
synthetic phenotype when seeded onto the aligned scaffolds, which is of a particular 
importance in new blood vessel formation [134]. 
A family of biodegradable poly(ester amide)s (PEA)s was explored in our laboratory to 
fabricate electrospun nanofibers [135, 136]. The rationale for exploring PEAs is that they 
combine the favorable properties of both polyesters and polyamides – the tunability in the 
degradation rate via the ester groups and mechanical strength via the hydrogen bonding of the 
amide groups. The ester and amide linkages promote both hydrolytic and enzymatic 
degradation, which should ensure a surface degradation mechanism [137], and this provides 
better prediction and control over the release profile. In addition, PEAs with tailored 
degradation rates can be synthesized with the careful selection of the monomers. Their 
degradation by-products include amino acids, which are found physiologically, limiting 
their potential systemic toxicity [138]. Unlike polyesters, PEA degradation results in less 
acidic by-products, avoiding significant pH decrease in the tissues and thus decreased host 
immune responses [139]. In this thesis, a PEA derived from the α-amino acid, L-
phenylalanine, was utilized to fabricate dual-loaded electrospun fibers for therapeutic 
angiogenesis application.  
 
2.9.3 Spatio-temporal Controlled Delivery of Angiogenic Factors 
Local concentration of angiogenic growth factors delivered by polymer-based delivery 
systems can be tuned by modifying the physical or chemical properties of these systems. 
The release of encapsulated growth factors is controlled by porosity, pore size, inter-pore 
distance, the degree of cross-linking, and degradation rate of the delivery system [17]. Pore 
size and porosity have also been found to affect host inflammation and angiogenesis [140]. 
Mooney and coworkers [141] reported that altering the composition of synthetic polymer 
such as PLGA can control the degradation rate to produce differential VEGF release 
profiles.  Delivery systems can be designed to release angiogenic growth factors in 
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response to specific signals from the cellular environment, including enzymes such as cell 
secreted proteinases [142, 143] and mechanical stimulation [144]. Polymer-based systems 
permitting sequential growth factors delivery; such as VEGF and PDGF-BB [95], VEGF 
and Angiopoietin-1 [145], or FGF-2 and PDGF-BB [38], have been demonstrated to 
promote mature and stable vessel formation more effectively than simultaneous delivery 
of the growth factors. 
Spatial gradients of growth factors in tissues of interest can be achieved by changing the 
placement of polymer vehicles, immobilizing insoluble ligands to localize cells of interest, 
or designing delivery systems to provide spatially distinct signals [17]. For example, a 
porous bi-layered PLG scaffold system locally presenting VEGF alone in one spatial 
region, and VEGF and PDGF-BB in an adjacent region was reported to produce spatially 
different vessel morphologies [146]. Accordingly, presenting pro- and anti-angiogenic 
factors at different sites in the polymer scaffold may produce diverse vascular structures 
[17]. Coupling of cell adhesive ligands such as Arg-Gly-Asp (RGD)  to the site of interest 
can also be used to control the region of vessels formation [147], and the nano-scale 
organization of RGD can affect EC adhesion and motility [148]. Novel 3D fabrication 
techniques can offer more opportunities to control the geometry and design of polymer-
based scaffolds [149], consequently making it possible to incorporate angiogenic growth 
factor releasing vehicles into micro or nano-scale electromechanical devices to have more 
accurate control over spatial and temporal presentation of these growth factors [150, 151]. 
Integrating therapeutic angiogenesis with nanomedicine strategies  may also offer more 
promising applications in regenerative medicine [152]. 
 
 Safety of Angiogenic Growth Factor Delivery 
Several safety concerns can arise from the delivery of angiogenic growth factors to induce 
therapeutic angiogenesis for treatment of ischemic cardiovascular disease. These concerns 
focus on the potential for pathological angiogenesis and the side effects of the delivered 
factor [153]. Animal studies and early clinical trials suggested several typical side effects 
associated with exposure to FGF-2 and VEGF. VEGF and FGF-2 are known to be 
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associated with systemic hypotension that occurs in a dose-dependent fashion; in this 
regard, the doses of FGF-2 leading to hypotension are substantially higher than for VEGF 
[154, 155]. It can be attributed to the upregulation of nitric oxide synthase and increased 
vessel wall permeability [156]. This has been shown in phase I trials at high doses or with 
rapid infusion of the angiogenic factors. FGF-2 has also been associated with proliferative 
membranous nephropathy leading to proteinuria in mice, but this has not been observed in 
clinical studies [157]. It is probably related to FGF-2 deposition in the heparan sulphate 
rich glomerular membrane [158]. For that reason, FGF-2 is not preferred to be used in 
patients with decreased creatinine clearance. Also, the adverse effects of VEGF and FGF 
include local oedema, anaemia, and thrombocytopenia [159, 160]. Growth factor gene 
therapy is usually accompanied with concerns of inflammatory responses due to exposure 
of patients to foreign genetic material and viral vectors [44, 46]. Over-expression of VEGF 
in mice has been associated with the formation of angiomas and vascular tumors [161, 
162]. The major concern is that the induction of angiogenesis may increase the risk of 
cancer. This concern arises from the well documented role of angiogenesis in tumor growth 
and metastasis [163]. To date, neither in vitro nor in vivo data exists to suggest that methods 
of therapeutic angiogenesis increase the risk of neoplastic growth or metastases. Oncogenic 
effects are not likely to occur with short-term dosing, appropriate patient selection, and 
localized delivery [74, 164, 165]. 
 
 Conclusions 
Ischemic heart disease causes millions of deaths worldwide. Data in the literature suggest 
that therapeutic angiogenesis may offer hope for ischemic heart disease patients who are 
ineligible to standard revascularization techniques. Moreover, if this proves to be the case, 
then expanded indications for therapeutic angiogenesis might then follow. Comprehensive 
understanding of the basic biology of neovascularization in physiological and pathological 
conditions will provide important information for the design of optimal delivery systems 
in terms of growth factor concentration, spatial and temporal release profiles, and their 
simultaneous or sequential presentation. Moreover, increased knowledge of the biological 
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mechanisms that regulate blood vessels growth and maturation, which highlights the 
complexity of molecular and cellular interactions taking place within the angiogenic 
microenvironment, is essential for targeting both neovascular induction and maturation. 
The combination of therapeutic angiogenesis with controlled delivery strategies could 
provide a minimally invasive revascularisation strategy that may be a major advance in the 
treatment of ischemic heart disease.  
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Chapter 3  
3 Controlled Delivery of Fibroblast Growth Factor-9 from 
Biodegradable Poly(ester amide) Fibers for Building Functional 
Neovasculature 
Overview: This chapter discusses the fabrication and optimization of PEA electrospun 
fibers and loading them with a model protein (BSA) and FGF9 using either blend or 
emulsion electrospinning techniques and their characterization in terms of morphological 
properties, in vitro release kinetics, bioactivity of the released growth factor, and cell 
viability and metabolic activity. 
 
 Abstract 
For building functional vasculature, controlled delivery of fibroblast growth factor-9 
(FGF9) from electrospun protein-analog fibers is an appealing strategy to overcome 
challenges associated with its short half-life. FGF9 sustained delivery could potentially 
drive muscularization of angiogenic sprouts and help regenerate stable functional 
neovasculature in ischemic vascular disease patients. Electrospinning parameters of FGF9-
loaded poly(ester amide) (PEA) fibers have been optimized, using blend and emulsion 
electrospinning techniques. In vitro PEA matrix degradation, biocompatibility, FGF9 
release kinetics, and bioactivity of the released FGF9 were evaluated. qPCR was employed 
to evaluate platelet-derived growth factor receptor-β (PDGFRβ) gene expression in NIH-
3T3 fibroblasts, 10T1/2 cells, and human coronary artery smooth muscle cells cultured on 
PEA fibers at different FGF9 concentrations. Loaded PEA fibers exhibited controlled 
release of FGF9 over 28 days with limited burst effect while preserving FGF9 bioactivity. 
                                                 

 A version of this chapter is published as a research article “Somiraa S. Said, J. Geoffrey Pickering and 
Kibret Mequanint, Pharmaceutical Research (2014), 31(12); 3335-3347”. Adapted with permission from 
Springer © 2014. 
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FGF9-loaded and unloaded electrospun fibers were found to support the proliferation of 
fibroblasts for five days even in serum-depleted conditions. Cells cultured on FGF9-
supplemented PEA mats resulted in upregulation of PDGFRβ in concentration and cell 
type-dependent manner. This study supports the premise of controlled delivery of FGF9 
from PEA electrospun fibers for potential therapeutic angiogenesis applications. 
Keywords: Electrospinning; Fibroblast growth factor-9; Poly(ester amide)s; Therapeutic 
angiogenesis. 
 
 Introduction 
Ischemic vascular diseases are characterized by inadequate delivery of blood and oxygen 
to tissues; coronary artery disease affects the heart, cerebrovascular disease affects the 
brain, and the peripheral arterial disease affects skeletal muscles and other internal organs 
[1]. The principal pathological process causing ischemic diseases is atherosclerosis, which 
is a progressive inflammatory condition that usually affects large arteries, in which the 
accumulation of lipids, inflammatory cells, and fibrous material in the inner arterial wall 
results in the occlusion of these arteries [2]. Some ischemic disease patients are ineligible 
for standard revascularization techniques due to poor overall health status or underlying 
comorbidities. Furthermore, a significant percentage of patients undergoing 
revascularization procedures do not meet the desired treatment outcome or experience 
restenosis, resulting in a poor prognosis and diminished quality of life, necessitating novel 
therapeutic alternatives for treatment of ischemic diseases [1].  
Therapeutic angiogenesis, which includes the administration of growth factors for new and 
stable blood vessel formation, is an appealing approach to simulate angiogenesis in order 
to improve tissue perfusion and accelerate tissue regeneration in several pathological 
conditions such as ischemic heart disease, critical limb ischemia, diabetic ulcers, and 
delayed wound healing, leading to the functional recovery of ischemic tissues. However, 
the short half-life of exogenously delivered growth factors results in their rapid clearance 
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from the application site following their delivery in a soluble form as an injection or 
infusion in the systemic circulation or tissue of interest [3]. One approach to overcome 
such limitations is the controlled delivery of growth factors at the desired site from fibers 
using either blend, coaxial or emulsion electrospinning techniques [4-7]. This can boost 
the stability of the growth factors and enable the sustained release of angiogenic factors in 
a biologically active form at the site of interest [8].  
Fibroblast growth factor-9 (FGF9) or glial activating factor is one of the FGF superfamily 
and relatively little is known regarding its physiological function [9]. It has higher 
specificity to fibroblast growth factor receptor-2/-3 isoforms [9-11], and was shown to 
demonstrate an elevated neointimal expression after arterial injury and contributes to 
smooth muscle cell proliferation [10]. Recently, it has been reported that even though FGF9 
did not itself stimulate angiogenesis, it was found to drive muscularization of angiogenic 
sprouts and that its delivery imparts stability, longevity, and the ability to regulate blood 
flow through vasoresponsiveness of the newly formed microvessels [12]. The FGF9-
induced layering of neovessels was suggested to be mediated by sonic hedgehog-PDGFRβ-
dependent signaling and it enhanced the ability of the neovasculature to receive flow and 
resist regression [12]. FGF9 delivery by means of an osmotic pump to ischemic hind limbs 
promoted neovascular maturation and recovery of limb function [12]. Therefore, FGF9 
delivery may be required in order to drive the angiogenesis process towards completion 
since angiogenic growth factors by themselves cannot efficiently produce vasoreactive 
neovessels [13]. Controlled-release biodegradable polymeric fibers can serve as a simple, 
low-cost and efficient alternative for implantable mini-infusion pumps for the delivery of 
FGF9, without the need of delivery system removal after consumption of the growth factor. 
Poly(ester amide)s (PEAs), successfully synthesized in our laboratory, are protein-analog 
polymers that were found to have the potential to promote vascular tissue regeneration 
owing to their biomimetic properties and favorable degradation profiles [14], for which 
bioactive molecules can be incorporated, potentially sustaining their release, enhancing 
their efficacy, and accelerating favorable cell-material interactions. Degradation products 
of PEAs derived from naturally occurring α-amino acids are nontoxic and can be well 
metabolized by the body. Moreover, PEA degradation is  accompanied by the release of 
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less acidic by-products compared to polyesters, thus avoiding pH decrease in the vicinity 
of the scaffold, usually resulting in inflammatory responses [15]. Nevertheless, surface 
eroding PEA scaffolds exhibit linear drug release kinetics [16], which provides better 
control of the drug release profile. Although electrospinning of a small number of PEAs 
have been reported [17-19], these PEA fibers were either prepared from low-molecular 
weight PEAs resulting in large diameter-fibers (from 0.64 to 3.5 µm) [17], or a polymer 
blend was required for electrospinning, where polycaprolactone was added to L-alanine-
based PEA as a viscosity modifier to facilitate electrospinning [18]. Moreover, in vitro 
degradation studies of other alanine-based PEA electrospun fibers showed that they were 
not practically degradable, where the weight loss was less than 6% after 305 days of 
incubation in phosphate buffered saline at 37 °C [19]. 
In this study, amino acid-based biodegradable protein-analog electrospun PEA fibers have 
been fabricated for controlled delivery of growth factors intended for therapeutic 
angiogenesis applications. The goal here is to prepare FGF9-loaded protein-analog fibers 
and characterize the fabricated fibers in terms of their morphological properties and in vitro 
degradation. The in vitro release kinetics were also studied together with the bioactivity of 
the released FGF9. The in vitro biocompatibility of the FGF9-loaded and unloaded 
electrospun fibers was tested using NIH-3T3, 10T1/2, and human coronary artery smooth 
muscle cells for potential therapeutic angiogenesis application 
 
 Materials and Methods 
3.3.1 Materials 
L-Phenylalanine, p-toluenesulfonic acid monohydrate, sebacoyl chloride, 1,4-butanediol 
and sodium carbonate (Alfa Aesar, Ward Hill, MA). Solvents, such as toluene, ethyl 
acetate, dimethyl sulfoxide (DMSO), chloroform (CHCl3) and glass distilled 
dichloromethane (Caledon Laboratories, Georgetown, ON) were used without further 
purification. Bovine serum albumin was purchased from Sigma-Aldrich (Milwaukee, WI) 
and BCA protein assay kit from Thermo Scientific Pierce Inc. (IL, USA). Recombinant 
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human fibroblast growth factor-9 (FGF9) and human FGF9 DuoSet ELISA kit were 
purchased from Cedarlane (Burlington, ON).  
 
3.3.2 Synthesis of Poly(ester amide) by Interfacial Polymerization 
The poly(ester amide) was prepared as previously reported [14]. In the first step, di-p-
toluenesulfonic acid salt monomer was prepared by acid-catalysed condensation. A 
suspension of L-phenylalanine (60.5 mM, 2.2 equivalents), p-toluenesulfonic acid 
monohydrate (66 mM, 2.4 equivalent), and 1,4-butanediol (27.5 mM, 1 equivalent) in 
toluene (100 mL) was heated to 140 ºC with stirring in a flask equipped with a Dean-Stark 
trap. The solution was heated at reflux for 48 h, and then the solvent was removed under 
vacuum. The resulting material was filtered and washed with toluene. The monomer was 
purified by dissolving in boiling deionized water (300 mL) followed by hot filtration, and 
the solution was left to recrystallize overnight at 4 ºC. The purification step was repeated; 
afterwards, the monomer crystals were filtered and dried under vacuum.  
In the second step, sebacoyl chloride (5 mM, 1 equivalent) was dissolved in glass distilled 
anhydrous dichloromethane (15 mL) and the solution was added drop-wise to an aqueous 
solution (15 mL) containing di-p-toluenesulfonic acid salt monomer (5.0 mM, 1 
equivalent) and sodium carbonate (10 mM, 2 equivalents), and allowed to react for 12 h. 
Upon completion of the reaction, the solution was rotovapped. The polymer was then 
washed with deionized water prior to purification via Soxhlet extraction with ethyl acetate 
for 48 h followed by drying under vacuum. 
 
3.3.3 Fabrication of PEA Electrospun Fibers 
The electrospinning setup was equipped with a High Voltage DC Power Supply (ES30P, 
Gamma high voltage, USA), a glass syringe (Becton, Dickinson and Co., 0.5 cc, NJ, USA) 
with a blunt-tip stainless steel needle (conducting spinneret) controlled by a syringe pump 
(KD101, KD scientific, USA), and a static collector covered with aluminum foil. The 
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process parameters including spinneret diameter (18 - 22 G) and applied voltage (15 - 20 
kV), and the formulation parameters including polymer concentration (5.5 - 7 %w/w) and 
solvent composition (Chloroform-to-dimethyl sulfoxide ratio) were optimized, in order to 
obtain bead-free fibers with uniform fiber diameter distribution. 
 
3.3.4 Characterization of PEA Electrospun Fibers  
Morphological analysis of the PEA fibers was performed using scanning electron 
microscopy (S-3400N SEM, Hitachi, Japan). Electrospun fibrous mat samples were 
sputter-coated with gold/palladium (K550X sputter coater, Emitech Ltd., UK) and scanned 
at a working distance of 10 mm and a constant accelerating voltage of 20 kV. Three SE 
micrographs of the electrospun mats were analysed using computerised ImageJ software 
(NIH, Bethesda, MD, USA) to quantitatively determine mean fiber diameter from ten 
random measurements for each image. For transmission electron microscopy (Phillips 
CM10 TEM), the fibers were electrospun directly on the TEM grids for 30 sec, and the 
samples were examined at 80 kV. 
 
3.3.5 In vitro Degradation Study  
Samples of the fibrous mats (1 × 1 cm2) were placed in a screw-capped glass vials filled 
with 10 mL of phosphate buffered saline (PBS 50 mM, pH 7.4) and removed at pre-
determined time-points, rinsed with deionized water and vacuum dried for 48 h at room 
temperature for further analyses. Samples at the different degradation time-points were 
analysed morphologically using SEM. The weight loss was determined by the following 
equation: Mass loss =[
(𝑀𝑖−𝑀𝑡)
𝑀𝑖
] × 100%, where, Mi is the initial dry weight of the fibrous 
mat at time 0 and Mt is the dry weight of the sample at the specific degradation time (after 
drying under vacuum). The molecular weights of the PEA fibers before and after 
degradation were determined using  a Waters system gel permeation chromatography 
(GPC) equipped with two PLgel 5µm (300 × 1.5 mm) columns at 85 °C and connected to 
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a PLgel guard column (Waters Ltd, Mississauga, ON). The eluent used was N,N-
dimethylformamide (DMF) with 10 mM lithium bromide  and 1% (v/v) triethylamine, and 
samples were injected (100 μL) at a flow rate of 1 mL/min and calibrated against 
polystyrene standards. Additional degradation studies were carried out in conditioned 
smooth muscle cell growth medium (CSmGM); human coronary artery smooth muscle 
cells (HCASMCs) were cultured in SmGM for 48 h, then the media was collected and used. 
Samples of 1 × 1 cm2 fibrous mats were immersed in 1 mL of the degradation medium at 
37 ºC, and the media were refreshed every week. Samples at different degradation time-
points were removed, rinsed with deionized water, vacuum dried at room temperature and 
analyzed morphologically using SEM. To rule out the effect of the incubation temperature, 
dried PEA fiber mats were kept in a vial at 37 oC as a control. 
  
3.3.6 Loading PEA Fibers with Model Protein and Fibroblast Growth Factor-9  
Bovine serum albumin (BSA) was incorporated into the PEA fibers using blend or 
emulsification electrospinning [5, 6]. The electrospinning parameters were adopted from 
the previously conducted studies for unloaded fibers. Briefly, the PEA was dissolved in 
chloroform and dimethyl sulfoxide (DMSO) at a ratio of (9:1). The polymer solution (0.5 
ml) was electrospun using a high voltage DC power supply set to 20 kV and a syringe with 
a blunt-tip stainless steel spinneret (22 gauge) kept at 8 cm from the grounded collector. 
The flow rate was kept at 0.1 mL/h using a syringe pump. In case of the blend 
electrospinning, BSA was dispersed in DMSO (1 µg/µL) and 100 µL were added to the 
polymer solution. While, for the emulsion electrospinning, 10 µL of stock BSA solution in 
PBS (10 µg/µL) were dropped and ultrasonicated in the polymer solution for 30 min in an 
ice bath. The same protocol was adopted for FGF9 loading, except for the lower initial 
loading (3 µg FGF9/ 0.5 mL polymer solution). 
 
 55 
  
3.3.7 Determination of Percentage Entrapment Efficiency 
 Four milligrams of loaded PEA fibers were dissolved in 0.5 mL of chloroform and the 
tube was vortexed to dissolve the polymer. Afterwards, 2.5 mL of PBS (pH 7.4) were added 
to extract the protein, and the system was centrifuged at 2000 rpm for 5 min to separate the 
organic and aqueous phases. The aqueous phase was collected for BSA or FGF9 
quantification using BCA protein assay kit (Thermo Scientific Pierce Inc., IL, USA) and 
ELISA assay kit (R&D systems, Inc., MN, USA), respectively. Three independent 
experiments on different PEA-loaded fiber batches each conducted in triplicate (n=9) were 
used to determine the percentage entrapment efficiency (% E.E.). 
 
3.3.8 In vitro Release Study of BSA and FGF9-loaded PEA Electrospun Fibers 
Samples of 1 × 1 cm2 fibrous mats were placed in a 24-well plate, and incubated with 1 ml 
of phosphate-buffered saline (PBS 50 mM, pH 7.4) under continuous agitation (100 
strokes/min), in a thermostatically controlled micro-plate shaker (VWR, USA) at 37°C. At 
pre-determined time intervals, the supernatant was collected and replenished with an equal 
volume of fresh buffer. The supernatants were immediately frozen at − 80°C until further 
measurements. The amount of BSA released was quantified by micro BCA protein assay 
kit (Thermo Scientific Pierce Inc., IL, USA), while the amount of FGF9 released was 
quantified by ELISA assay kit (R&D systems, Inc., MN, USA). The absorbance was 
measured using a micro-plate reader (UVM 340, Montreal Biotech Inc., Canada) and the 
unknown concentration was determined from a pre-constructed calibration curve and the 
% E.E. data.  
 
3.3.9 Bioactivity Assay of the Released Growth Factor 
Bioactivity of the released growth factor from the electrospun scaffolds was assayed by in 
vitro evaluation of (NIH-3T3 cell line) mouse embryonic fibroblast metabolic activity. 
NIH-3T3 cells were seeded in 96-well plates at a density of approximately 3000 cells/well 
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with 100 µL/well of advanced DMEM (GIBCO®, Invitrogen, Burlington, ON, Canada) 
containing 5% FBS, 1% antibiotics and 2 mM L-glutamine, in addition to 100 µL of the 
released FGF9 in PBS. After an incubation time of 48 h, cell metabolic activity was 
determined by MTT assay following the manufacturer’s protocol (Vybrant®, Invitrogen, 
Burlington, ON, Canada). As a positive control, soluble FGF9 was added to the NIH-3T3 
cells in amounts equivalent to those released from the FGF9-loaded scaffolds. The amount 
of added growth factor was calculated from the in vitro release data, combining release 
time points into: early-released FGF9 (from Day 1 to Day 14) and late-released FGF9 (from 
Day 15 to Day 28) for both blend and emulsion electrospinning techniques. Cells cultured 
without FGF9 served as a negative control. 
 
3.3.10 Cell Viability and Confocal Microscopy  
Cell viability and metabolic activity on 2D PEA films (20 µL of 1% w/v PEA in DMF 
solvent casted), unloaded and FGF9-loaded 3D PEA electrospun scaffolds were quantified 
by MTT colorimetric assay. Circular patches (4 mm in diameter) of electrospun mats on 
aluminium foil were punched and affixed to a 96-well cell culture plate (BD Falcon™, 
Franklin Lakes, NJ) using silicone grease, sterilized by immersion in 70% ethanol (200 
µL) for 30 min, and allowed to dry for one hour under germicidal UV light, before 
conditioning overnight in Hank’s balanced salt solution (HBSS, 200 µL; Invitrogen 
Canada, Burlington, ON). NIH-3T3 cells were seeded onto samples at an initial cell density 
of approximately 3000 cells/well and cultured for five days in advanced DMEM containing 
5% FBS or serum-depleted conditions, and maintained in a humidified incubator at 37 °C 
and 5% CO2. At pre-determined time points, the medium was refreshed (100 µL), followed 
by the addition of 10 µL of 12 mM MTT solution to each well to make the final 
concentration 1.10 mM and then incubated at 37°C for 4h. Yellow MTT salts are reduced 
to water-insoluble purple formazan by metabolically active cells. Afterwards, 100 µL 10% 
(w/v) SDS/HCl was added to solubilize the formazan, and further incubated at 37 °C for 
18 h. Finally, the colored product was transferred to 96-well plate and the absorbance was 
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recorded at 570 nm by a micro-plate reader. Controls of TCPS were included in the 
experiments.  
For confocal microscopy, NIH-3T3 fibroblasts, 10T1/2 cells, and HCASMCs were seeded, 
in 24-well plate at an initial cell density of approximately 2000 cells/cm2, on control glass 
coverslips, PEA films, FGF9-loaded PEA fibers, and PEA fibers with exogenous soluble 
FGF9, for three days. Cells were washed with pre-warmed PBS immediately prior to fixing 
at ambient temperature for 15 min in 4% formaldehyde solution (1 mL; EMD Chemicals) 
in divalent cation-free PBS. Following three washes in PBS, HCASMCs were 
permeabilized with 0.1% Triton X-100 (0.5 mL; VWR International, Mississauga, ON) in 
PBS for 5 min and again washed three times with PBS. The cells were incubated with 1% 
BSA in PBS (0.5 mL; Sigma-Aldrich, Oakville, ON) for 30 min at ambient temperature 
prior to their incubation with AlexaTM Fluor 568-conjugated phalloidin (1:50 dilution; 
Invitrogen Canada, Burlington, ON) in the dark for 1 hour at ambient temperature followed 
by another three washes with PBS. The cells were then counterstained with 4′-6-diamidino-
2-phenylindole dyhydrochloride (DAPI, 300 nM in PBS, 0.5 mL; Invitrogen Canada, 
Burlington, ON) for 5 min to label the nuclei and again washed three times with PBS. No.1 
coverslips were mounted on microscope slides with Trevigen® Fluorescence Mounting 
Medium (Trevigen INC., Gaithersburg, MD). Samples were analyzed with a Zeiss LSM 5 
Duo confocal microscope with nine laser lines and appropriate filters (Carl Zeiss, Toronto, 
ON, Canada). 
 
3.3.11 RNA Isolation and Quantitative Real-time PCR Analysis 
Real-time Polymerase Chain Reaction (qPCR) combined with reserve transcription was 
used to quantify messenger RNA (mRNA) expression of PDGFR-β in NIH-3T3 cells 
grown on control (TCPS), PEA fibers, FGF9-loaded PEA fibers, and PEA fibers with 
exogenous soluble FGF9, at a density of 2.5 × 105 cells/sample, for 24 h. Moreover, q-PCR 
was employed to study the effect of FGF9 concentration gradient on PDGFR-β gene 
expression in different cells (NIH-3T3, 10T1/2, and HCASMCs) grown on control (TCPS) 
and PEA fibers with exogenous soluble FGF9 of different concentrations (0, 8, 25, and 50 
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ng/mL). Total RNA from the cells was extracted using Trizol® reagent (Invitrogen, 
Burlington, Canada) following the manufacturer’s protocol. Complementary DNA 
(cDNA) was synthesized using 1µg of total RNA primed with oligo12-18 as described in 
SuperScriptTM (Invitrogen, Canada). Quantitative real-time PCR was conducted in 10 µl 
reaction volumes, using a CFX-96 Touch™ Real-time system C1000 Thermal Cycler (Bio-
Rad, Mississauga, Canada) and gene expression of mouse and human PDGFR-β were then 
determined with iQTM SYBR® Green Supermix (Bio-Rad) according to the recommended 
protocol of the manufacturer. PDGFR-β forward primer: 
5′- GGAGATTCGCAGGAGGTCAC-3′, reverse primer: 
5′- ATAGCGTGGCTTCTTCTGCC-3′, GAPDH forward primer: 
5′- GTGGTCTCCTCTGACTTCAACA-3′, reverse primer: 
5′- TTGCTGTAGCCAAATTCGTTGT-3′. Amplification entailed 40 cycles of: 
denaturation 95°C (15 s), annealing 55°C (60 s), and extension 72°C (30 s). The relative 
mRNA expression in the cells was normalized to the housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) with at least three repeats per experimental group 
and expressed as a relative ratio using the CFX ManagerTM 3.0 analysis software (Bio-Rad, 
Mississauga, Canada). 
 
3.3.12 Statistical Analysis 
Data is presented as mean ± SEM for experiments conducted in triplicate. Statistical 
analysis was conducted with t-test or one-way ANOVA followed by Tukey’s multiple 
comparison test using GraphPad Prism 4 software (GraphPad Software, Inc., CA, USA). 
Probability values less than 0.05 were considered statistically significant. 
 
 59 
  
 Results and Discussion 
3.4.1 Synthesis of PEA by Interfacial Polymerization 
In this study, the PEA was synthesized by interfacial polymerization as previously reported 
and the results were consistent with previous data [14]. The synthesized PEA, whose 
chemical structure is shown in Figure 3-1 was designated as “8-Phe-4”, whereby the 8 
stands for the number of methylene groups contributed by the sebacic acid (diacid), the 
Phe is designated for L-phenylalanine (amino acid) and the 4 represents the number of 
methylene groups in the butanediol moiety (diol). The structure of 8-Phe-4 was confirmed 
through 1H NMR.  Interfacial polymerization is an irreversible condensation reaction 
occurring at the interface between two immiscible liquids; one of them is usually a water 
phase containing the di-functional monomer and inorganic base to activate the diol and 
neutralize the by-product acid, the other phase is an organic solvent containing the diacid 
chloride. Interfacial polymerization is preferred because it is rapid, less affected by 
impurities, and produces PEAs of higher molecular weights than solution 
polycondensation reactions [20]. 
 
Figure 3-1: Chemical structure and corresponding H1-NMR of 8-Phe-4. 
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3.4.2 Fabrication and Optimization of PEA Electrospun Fibers 
PEA fibers were prepared using a solution electrospinning technique. The goal was to 
develop bead-free fibers from high molecular weight-PEA and optimize the 
electrospinning parameters to obtain fibers of average fiber diameter between 100 - 500 
nm, in order to mimic the extracellular matrix fiber diameter. It is clear from the 
electrospinning processes literature that the structure and morphology of the produced 
fibers are determined by a synergistic effect of formulation and process parameters. 
Formulation parameters including the effect of polymer concentration and solvent 
composition on fiber morphology were studied. Increasing the polymer concentration in 
100% chloroform (CHCl3) from 5.5 to7% w/w, electrospun at 8 cm/20 kV, 22 G, and 0.1 
mL/h flow rate resulted in increasing the average fiber diameter from 445 to 655 nm as 
illustrated in Figure 3-2 (A-C). This also led to decreased bead formation, where they 
transformed from spherical-shaped beads to spindle-like beads to defect-free fibers. This 
is consistent with previous data reporting that increasing the polymer solution viscosity by 
increasing its polymer concentration yielded uniform fibers with fewer beads and junctions 
[21]. However, at polymer concentration of 7% w/w, the polymer solution was too viscous, 
and chloroform evaporated too fast (B.P. = 61°C), which resulted in drying out of the 
polymer at the needle tip. This phenomenon was previously reported for concentrated 
solutions (and therefore too viscous) [22], which in this study interrupted the 
electrospinning process several times, demanding for an alternative solvent system.  
 
Regarding the effect of solvent composition and conductivity on the fiber morphology, the 
use of a binary solvent system of chloroform and dimethylsulfoxide, CHCl3/DMSO (9:1), 
instead of 100% CHCl3 resulted in eliminating the beads as illustrated in Figure 3-2 (D-F). 
This can be attributed to the high dielectric constant of DMSO (ε = 46.6) contributing to 
the increased conductivity of the polymer solution. It has been shown that increasing the 
polymer solution conductivity can be used to produce more uniform fibers with fewer 
beads, and solvents that had sufficiently high values of dielectric constant were found to 
be used successfully in electrospinning [21, 23]. Further increase in the DMSO 
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concentration resulted in fiber fusion, due to residual DMSO that could not evaporate (B.P. 
= 189 °C) from the polymer solution before the fibers hit the grounded collector. 
 
 
 
Figure 3-2: Optimization of formulation electrospinning parameters. 
Effect of polymer concentration on fiber morphology and fiber diameter, 8-Phe-4 in CHCl3 
(A) 5.5% w/w, (B) 6% w/w, and (C) 7% w/w. Effect of solvent composition on fiber 
morphology and diameter, 6% w/w 8-Phe-4 in CHCl3/DMSO ratio of (D) (10:0), (E) (9:1), 
and (F) (8:2), electrospun at 8cm/20kV, 22 G, and 0.1 mL/h flow rate. 
 
Processing parameters such as the applied voltage and spinneret diameter were also 
studied. Figure 3-3 (A-C) illustrates the effect of the applied voltage on fiber morphology 
and diameter. In the case of single solvent system of CHCl3, reducing the applied voltage 
from 20 to 15 kV resulted in decreased fiber diameter from 380 to 255 nm; however, it did 
not affect the fiber morphology. It has been shown that increased voltages produces jets 
with larger diameters and ultimately leads to the formation of several jets and the presence 
of beads in many polymeric systems [21]. In regards to the effect of spinneret diameter, 
6% w/w PEA in CHCl3/DMSO (9:1) was electrospun at 20 kV, 8cm, and 0.1 mL/h flow 
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rate with increasing needle gauge from 18 to 22 gauge, which corresponds to decreasing 
the spinneret diameter. This resulted in a reduction in the mean fiber diameter from 345 to 
250 nm Figure 3-3 (D-F) and more uniform fiber diameter distribution as shown in Figure 
3-3 (G-I). Based on the optimization of PEA electrospun fibers data, the elelectrospinning 
parameters were fixed at 6% w/w PEA in CHCl3/DMSO (9:1), electrospun at 20 kV, 8cm, 
22 guage needle, and 0.1 mL/h flow rate in all subsequent experiments. 
 
 
Figure 3-3: Optimization of process electrospinning parameters.  
Effect of applied voltage on fiber morphology and diameter, electrospun fibers of 6% w/w 
8-Phe-4 in CHCl3 at (A) 20 kV, (B) 17 kV, and (C) 15 kV. Effect of spinneret diameter on 
fiber morphology and diameter, 6% w/w 8-Phe-4 in CHCl3/DMSO (9:1) was electrospun 
from (D) 18 gauge, (E) 20 gauge, and (F) 22 gauge needle. Histograms of fiber diameter 
distribution for 8-Phe-4 fibers electrospun from (G) 18 gauge, (H) 20 gauge, and (I) 22 
gauge spinneret. 
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3.4.3 In vitro Degradation Study  
Scaffold degradation in phosphate buffered saline (pH 7.4) at 37 ºC for a period up to four 
weeks was examined qualitatively using scanning electron microscopy and quantitatively 
by mass loss determination and molecular weight analysis using GPC. The effect of 
temperature alone during the degradation of the fibers was excluded by incubating control 
dry fiber mats at 37 ºC inside a glass vial.  Since the glass transition temperature of 8-Phe-
4 is 41 ºC, no observable changes on the fiber morphology such as fiber flattening and 
subsequent fusion over the 28 days was anticipated (top panel in Figure 3-4 A).  
 
 
Figure 3-4: In vitro degradation of PEA electrospun fibers at 37 ºC for 28 days. 
(A) SE micrographs for fibers in PBS (pH = 7.4) and conditioned human smooth muscle 
cell growth medium, the control is dry PEA fibers kept at 37 ºC. (B) Percentage mass loss 
of PEA fibers in PBS (pH = 7.4) at 37 ºC at different time points (n=3) and (C) molecular 
weight analysis using gel permeation chromatography. 
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Scanning electron (SE) micrographs showed that scaffolds incubated in PBS preserved 
their fibrous structure over the four-week study period, with negligible morphological 
changes when compared to the control at 37 ºC (middle panel in Figure 3-4 A). Moreover, 
quantitative analysis showed 21% mass loss over the 28-day study period together with 
insignificant change in average number molecular weight (Mn) over the four weeks (Figure 
3-4 B and C). When these samples were incubated in PBS for 84 days (12 weeks), the 
fibers lost 48% of their mass while the molecular weight remained nearly constant. The 
linear decrease in mass (r2 = 0.99), coupled with constant molecular weight indicate that 
the PEA scaffold degradation is dominated by surface erosion [18, 24]. The polydispersity 
indices of the samples during the incubation time in PBS for 12 weeks were 2.88 ± 0.15, 
further supporting the absence of bulk degradation. Additionally, the effect of bio-relevant 
media on the degradation of the PEA fibers was studied, so additional degradation studies 
were carried out in a conditioned smooth muscle cell growth medium (CSmGM); human 
coronary artery smooth muscle cells (HCASMCs) were cultured in SmGM for 48 h, in 
which the HCASMCs would have consumed the nutrients necessary for their growth and 
secreted their metabolites and other products relevant to growth in culture, then the media 
was collected and used for the degradation study. The SE micrographs showed that the 
fibers did withstand this bio-relevant medium with some fiber swelling and fusion starting 
from Week 3 (bottom panel in Figure 3-4 A). The in vitro degradation data suggests that 
surface eroding PEA electrospun fibers can be employed for controlled delivery of 
bioactive molecules in biorelevant conditions.  
 
3.4.4 In vitro Release Study of Loaded PEA Electrospun Fibers 
The model protein, bovine serum albumin (100 µg BSA/cm2), was successfully loaded into 
the PEA fibers using blend or emulsification electrospinning [5, 6].  The percentage 
entrapment efficiency (% E.E.) for blend and emulsion electrospun BSA-loaded fibers was 
93% ± 3 and 73% ± 4, respectively.  The lower entrapment efficiency for the emulsion 
electrospun fibers is related to the relatively higher viscosity of the emulsified 
protein/polymer mixture compared to the blend where the protein was dissolved. 
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Transferring a more viscous emulsion from an emulsification vial to an electrospinning 
syringe causes some material loss. The residual protein/polymer solution left on the inner 
wall of the syringe after electrospinning also accounts for some material loss. 
 Samples of 1 × 1 cm2 fibrous mats were placed in a 24-well plate, and incubated with 1 
ml of phosphate-buffered saline (PBS 50 mM, pH 7.4) under continuous agitation (100 
rpm/min) at 37 °C. At predetermined time intervals, the amount of BSA released was 
quantified by BCA protein assay kit. BSA release was sustained over the 28-day study with 
a limited burst effect and 80% BSA liberation from the blend electrospun BSA-loaded PEA 
fibers (Figure 3-5 A). Given that the mass loss during the 28 days is 21%, the higher BSA 
release is related to its higher initial protein loading. Incorporation of higher amounts of a 
protein into the fibers is believed to be a driving force for protein molecules to migrate 
toward the surface of the fiber during electrospinning [25]. The absence of burst release 
highlighted BSA uniform entrapment with the polymer solution [26], resulting in perfect 
inclusion within the fibers [27], while the sustained release pattern confirmed the adequate 
structural integrity of the fibers throughout the study. For emulsion electrospun fibers, the 
release profile showed a decreased BSA release rate in comparison with blend electrospun 
fibers, reaching 37% at Day 28. This is predictable based on the notion that BSA is 
encapsulated in the aqueous vesicles (as demonstrated in Figure 3-5 C), which can be 
referred to as a “diffusion-across-a-barrier type release system” [16]; this requires the 
degradation of the polymeric matrix, then subsequent diffusion of BSA from the vesicles 
across the outer barrier layer. During an emulsion electrospinning process, the emulsion 
droplets move from the surface to the center to achieve their highest accumulation along 
the axial region [6, 28]. This inward migration of emulsion droplets is caused by rapid 
evaporation of the solvents during electrospinning. As the organic solvent evaporates faster 
than water, the viscosity of the outer layer of a fiber increases more rapidly than that of  its 
inner layer resulting in a viscosity gradient between the aqueous droplets and the polymer 
matrix, which directs the emulsion droplets to settle into the fiber core rather than on the 
surface [16, 29]. 
BSA-loaded PEA fibers prepared by both electrospinning techniques followed a time-
dependent power law function: 
𝐌𝐭
𝐌∞
 = 𝐤 𝐭𝐧, where, 
𝐌𝐭
𝐌∞
 is the fractional release, k is a 
 66 
  
structural/geometric constant, t is the time and n is the release exponent representing the 
release mechanism. The n values of blend and emulsion electrospun BSA-loaded fibers 
were 0.62 and 0.58, respectively. For cylindrical constructs (for which the individual fiber 
can be modelled), an n value between 0.45 and 0.89 indicates a coupled matrix degradation 
and biomolecule diffusion release mechanism [30].  
 
Figure 3-5: In vitro release study of (A) BSA-loaded PEA fibers and (B) FGF9-loaded 
PEA fibers, using blend and emulsion electrospinning techniques, in PBS (pH=7.4) at 
37 ºC (n=3).  
(C) TEM of BSA-loaded PEA fibers and (D) TEM of FGF9-loaded PEA fibers, using the 
emulsion electrospinning technique (arrows are pointing to the aqueous vesicles). (E) 
Bioactivity study of FGF9 released from FGF9-loaded PEA fibers using MTT assay. Two-
release time points were tested; early-released FGF9 (from Day 1 to Day 14) and late-
released FGF9 (from Day 15 to Day 28) for blend and emulsion techniques. Positive 
controls of soluble FGF9 were included in the experiment. Data represents mean ± SEM 
from three independent experiments (* p < 0.05). 
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Following the proof-of-concept of incorporating a model protein into PEA electrospun 
fibers, FGF9 was loaded into the PEA fibers adopting both electrospinning techniques. The 
% E.E. of FGF9 was 86% ± 3 and 80% ±3 for blend and emulsion electrospun FGF9-
loaded fibers, respectively, using ELISA kit. FGF9-loaded fibers showed a similar release 
profile (Figure 3-5 B) with a significant decrease in the overall release rate, due to the lower 
initial protein loading (~120 ng/cm2). Similarly, the release exponent for blend and 
emulsion electrospun FGF9-loaded fibers was 0.67 and 0.59, respectively, indicating also 
a non-Fickian diffusion mechanism. Although the ultimate goal is to deliver FGF9 in vivo, 
BSA release studies were also conducted in this work.  The rationale for using BSA was 
two-fold: i) it is a widely studied model protein in controlled-release studies and, ii) it is a 
large protein (66.5 kDa) compared with FGF-9 (23 kDa) allowing us to study the capability 
of PEA fibers to release proteins of different sizes in a similar mechanism. The data (Figure 
3-5 A and B) showed the release mechanism for both proteins was the same suggesting 
that PEA electrospun fibers had shown versatility for loading different bioactive molecules 
(BSA and FGF9). The ability to introduce bioactive molecules into these fibrous 
electrospun meshes, through these aqueous pouches opens a new path to therapeutic agent 
delivery. 
  
3.4.5 Bioactivity Assay of the Released Growth Factor 
A metabolic activity-based assay was used to assess the bioactivity of FGF9 released at 
early (Day 1 - Day 14) and late (Day 15 - Day 28) collective time points from the PEA 
electrospun fibers using blend and emulsion techniques. The proliferating cell number was 
determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay on NIH-3T3 fibroblasts incubated for 48 h with media containing released FGF9 or 
equivalent amounts of soluble FGF9 calculated from the in vitro release data (positive 
control). There was no significant difference (p < 0.05) in metabolic activity between the 
released and control FGF9 (Figure 3-5 E). These results indicate that FGF9 released from 
the fibers, prepared either by blend or emulsion techniques, was bioactive up to 28 days.  
It is worth noting that the emulsion late-released (ELR) time point did not show a 
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significant difference from the untreated control (no FGF9 added), which can be attributed 
to the lower released amount of FGF9 in case of ELR in comparison with the other three 
tested conditions. 
 
3.4.6 Cell Viability and Confocal Microscopy 
For evaluation of the PEA electrospun fibers in vitro biocompatibility as potential drug 
delivery vehicle for bioactive molecules, cell viability on FGF9-loaded 3D fibers was 
assessed using the MTT assay and compared to 2D PEA films and unloaded 3D fibers. For 
this section and the following one, FGF9-loaded PEA fibers prepared by emulsion 
electrospinning instead of blend electrospinning were used for two reasons: (i) to provide 
a maximum protection for FGF9 from the organic solvent (i.e. chloroform) during 
electrospinning, (ii) the long-term goal is to use the fibers as a dual growth factor delivery 
system (the first one for inducing angiogenic sprout formation and the second one to recruit 
mural cells for neovessel maturation and functionality after the formation of the endothelial 
tubes). Since FGF9 release is needed for neovessel maturation, its delayed release is 
beneficial.  
As shown in Figure 3-6, 2D PEA films, and both FGF9-loaded and unloaded fibers 
supported fibroblast viability for up to five days, in the case of 5% FBS (Serum+) 
conditions. In the case of serum-depleted (Serum−) conditions, the unloaded and FGF9-
loaded 3D PEA fibers maintained cell viability and metabolic activity through the five-day 
study, whereas 2D PEA films supported only the survival of cells. Baker and Southgate 
[31] attempted to culture stromal cells on 3D polystyrene fibers in serum-depleted 
conditions, but stromal cells failed to adhere to the polystyrene fibrous scaffold in the 
absence of serum; in contrary to this, PEA electrospun fibers were able to support 
metabolically active fibroblasts in serum-depleted conditions, which could be attributed to 
potential peptide linkages imparted by the amino acid-based PEA fibers. 
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Figure 3-6: NIH-3T3 cell viability study on 2D PEA films (1% w/v), unloaded and 
FGF9-loaded 3D PEA emulsion electrospun fibers for 5 days, in Serum+ (5% FBS) 
and Serum- (serum depleted; 0.05% FBS) conditions, using MTT assay.  
Data represents mean ± SEM from three independent experiments. Student t-test was 
conducted between PEA fibers group and FGF9-loaded PEA fibers group at the same 
conditions and the same time point (* p < 0.05). 
 
To further assess the PEA electrospun fibers as a potential sustained-delivery vehicle for 
FGF9, the interactions with different cell types (NIH-3T3, 10T1/2, and HCASMCs) were 
examined using confocal microscopy. FGF9 has reported proliferative effect on 3T3 [32, 
33] and smooth muscle cells [10, 12].  As for 10T1/2 cell line, it is a smooth muscle 
precursor cell type that is commonly used for in vitro SMC phenotype studies because of 
its ability to maintain a stable phenotype in culture and even can be pushed toward an SMC 
state [34]. The cells showed good attachment and spreading on glass control and 2D PEA 
surfaces, and displayed interaction and infiltration in case of the 3D PEA electrospun fibers 
either FGF9-loaded or with exogenous supplementation of FGF9 as shown in Figure 3-7. 
The PEA fibers had inherent autofluorescence in the green channel, which was obscured 
in case of HCASMCs (Figure 3-7 K&L) due to the use of different culture medium 
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(Medium 231 supplemented with SMGS, GIBCO®, Invitrogen, Burlington, ON, Canada). 
Biodegradable PEAs have been previously reported to support attachment, spreading, and 
proliferation of human coronary artery smooth muscle cells, bovine aortic endothelial cells, 
and fibroblasts [14, 18, 35, 36]. Together with the fact that 3D scaffolds play an important 
role in guiding cells to produce their own extracellular matrix and control phenotype 
differentiation [37, 38], by providing both mechanical and biological cues, PEA 
electrospun fibers were found to support cell growth even in serum-depleted conditions. 
This data highlights the potential expanding applications of PEA fibers in drug delivery 
and tissue engineering. 
 
 
Figure 3-7: Confocal microscopy images of NIH-3T3, 10T1/2, and HCASMCs. 
Cells seeded at 2000 cells/cm2 for 3 days on glass coverslips (control), PEA films, PEA 
fibers with exogenous FGF9, and FGF9-loaded PEA fibers cultured in Serum+ media, 
showing F-actin (red), nuclei (blue), and PEA fibers (green). Scale bar = 40 μm. 
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3.4.7 RNA Isolation and Quantitative Real-time PCR Analysis  
To understand the signaling pathways underlying the reported FGF9-induced investment 
of neovessels by SMCs, the expression of platelet-derived growth factor receptor-β 
(PDGFRβ), which is one of the downstream signaling molecules in FGF9-stimulated 
SMCs was studied. PDGFRβ is a well-documented regulator of SMC migration [39] and 
therefore a potential mediator of FGF9-induced vessel maturation. Real-time Polymerase 
Chain Reaction (qPCR) preceded with reserve transcription was used to quantify 
messenger RNA (mRNA) expression of PDGFRβ in NIH-3T3 cells grown on control 
(TCPS), PEA fibers, FGF9-loaded PEA fibers, and PEA fibers with exogenous soluble 
FGF9, at a density of 2.5 × 105 cells/sample, for 24 h. q-PCR analysis of PDGFRβ 
expression showed insignificant difference between NIH-3T3 cells seeded on PEA fibers, 
FGF9-loaded fibers, or PEA fibers with exogenous FGF9 (~2.5 ng/mL, equivalent to the 
amount released from the FGF9-loaded PEA fibers after 24 h) as illustrated in Figure 3-8A, 
suggesting that the FGF9 exogenously supplemented to PEA fibers is equivalent to the 
released FGF9 from the loaded PEA fibers. Thus, the FGF9 exogenously supplemented 
PEA fibers were selected to map the effective FGF9 concentration required for PDGFRβ 
upregulation, for future loading into the PEA fibers. Consequently, the effect of FGF9 
concentration on PDGFRβ gene expression was further studied in different cells (NIH-3T3, 
10T1/2, and HCASMCs) seeded on control (TCPS) and PEA fibers with exogenous soluble 
FGF9 of different concentrations (0, 8, 25 and 50 ng/mL). The q-PCR data showed 
significant upregulation in the PDGFRβ expression at the lowest tested FGF9 
concentration (8 ng/mL) for NIH-3T3 and 10T1/2 cells (Figure 3-8 B and C). In contrast, 
the highest tested FGF9 concentration (50 ng/mL) was the concentration that resulted in 
significant upregulation in the case of HCASMCs (Figure 3-8 D). Recent studies have 
shown that pre-treatment of SMCs with FGF9 (100 ng/ml) for 24 h was found to increase 
their chemotactic response to PDGF-BB [40], which is a ligand for PDGFRβ and a growth 
factor necessary for mural cell recruitment during development and can promote vascular 
stability [41]. As well, there was substantial increase in PDGFRβ expression in SMC pre-
exposed to increasing concentrations of FGF9 (10 - 100 ng/mL) [12]. Furthermore, when 
a PDGFRβ blocking antibody was added to angiogenic implants, it did not affect their 
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vascularity after 2 weeks but reduced the number of vessels invested by mural cells 
expressing smooth muscle α-actin [12]. The current findings support the premise that FGF9 
is a regulator of PDGFRβ expression, which is the receptor necessary for FGF9-induced 
mural cell recruitment, and that the critical concentration of FGF9 varies between mouse 
fibroblasts, 10T1/2 cells, and human smooth muscle cells. This study may provide 
important platforms for therapeutic angiogenesis and tissue engineering applications.  
 
 
Figure 3-8: (A) Quantitative real-time PCR analysis of PDGFR-ß expression for 
NIH-3T3 cells seeded on FGF9-loaded emulsion electrospun fibers and PEA fibers 
with exogenous FGF9 for 24 h.  
The effect of FGF9 concentration gradient on PDGFR-ß gene expression in (B) NIH-3T3 
fibroblasts, (C) 10T1/2 cells, and (D) HCASMCs, seeded on TCPS (control) and PEA 
fibers with exogenous FGF9 for 24 h. Data represents mean ± SEM, * indicates p < 0.05 
and ** indicates p < 0.01 (n=3). 
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 Conclusions 
Biodegradable poly(ester amide) fibers were successfully fabricated using electrospinning 
techniques. Bead-free fibers of mean fiber diameter ~250 nm and uniform fiber diameter 
distribution were produced using a binary solvent system of chloroform and DMSO (9:1). 
PEA electrospun fibers preserved their fibrous structure over the four-week in vitro 
degradation study in PBS (pH 7.4) and conditioned smooth muscle cell growth medium at 
37 °C. Loaded PEA fibers exhibited controlled-release of BSA and FGF9 over 28 days 
with a limited burst effect for both blend and emulsion electrospun fibers and preserved 
FGF9 bioactivity. Moreover, the FGF9-loaded PEA elecrospun fibers were found to 
maintain the metabolic activity of mouse fibroblasts for up to five days. Finally, q-PCR 
analysis suggests that FGF9 is a stimulator of PDGFRβ expression, which is the receptor 
necessary for FGF9-induced mural cell recruitment and vessel maturation. This data 
supports the premise of FGF9 sustained delivery from PEA electrospun fibers and its 
potential application in therapeutic angiogenesis and regenerative medicine. Future work 
is required to examine dual loading of angiogenic growth factors and evaluating the 
induced angiogenesis in vitro and in vivo. 
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Chapter 4  
4 Concurrent and Sustained Delivery of FGF2 and FGF9 from 
Electrospun Poly(ester amide) Fibrous Mats for Therapeutic 
Angiogenesis  
Overview: This chapter discusses the dual loading of the PEA electrospun fibers with 
FGF2 and FGF9 using a mixed blend and emulsion electrospinning technique, and studies 
the effect of the dual-loaded PEA electrospun fibrous scaffolds on endothelial cell tube 
formation and directed smooth muscle cell migration. Moreover, it investigates the 
inflammatory host response in vitro using THP-1 human monocytes and in vivo by 
subcutaneous implantation into B6 mice. 
 
 Abstract 
Therapeutic angiogenesis has emerged as a potential strategy to treat ischemic vascular 
diseases. However, systemic or local administration of growth factors is usually inefficient 
for maintaining the effective concentration at the site of interest due to their rapid clearance 
or degradation. In this study, a differential and sustained release of an angiogenic factor; 
fibroblast growth factor-2 (FGF2), and an arteriogenic factor; fibroblast growth factor-9 
(FGF9), from α-amino acid-derived biodegradable poly(ester amide) (PEA) fibers was 
reported towards targeting neovessel formation and maturation. FGF2 and FGF9 were 
dual-loaded using a mixed blend and emulsion electrospinning technique, and exhibited 
differential and sustained-release from PEA fibers over 70 days with preserved bioactivity. 
In vitro angiogenesis assays showed enhanced endothelial cell (EC) tube formation and 
                                                 

 A version of this chapter is published as a research article “Somiraa S. Said, Caroline O’Neil, Hao Yin, 
Zengxuan Nong, J. Geoffrey Pickering and Kibret Mequanint, Tissue Engineering Part A (2016)”. Adapted 
with permission from Mary Ann Liebert © 2016. 
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directed-migration of smooth muscle cells (SMCs) to PDGF-BB, and stabilized EC/SMC 
tube formation. FGF2/FGF9-loaded PEA fibers did not induce inflammatory responses in 
vitro using human monocytes or in vivo after their subcutaneous implantation into mice. 
Histological examination showed that FGF2/FGF9-loaded fibers induced cell niche 
recruitment around the site of implantation. Furthermore, controlled in vivo delivery of 
FGF9 to mouse tibialis anterior muscle resulted in a dose-dependent expansion of 
mesenchymal progenitor cell-like layers and ECM deposition. The data suggests that the 
release of FGF2 and FGF9 from PEA fibers offers an efficient differential and sustained 
growth factor-delivery strategy with relevance to therapeutic angiogenesis. 
Keywords: Electrospinning; Fibroblast growth factor-2; Fibroblast growth factor-9; 
Poly(ester amide)s; Therapeutic angiogenesis. 
 
 Introduction 
Therapeutic angiogenesis, the induction of new blood vessel formation, has emerged as a 
potential approach to treat ischemia caused by coronary and peripheral arterial diseases [1]. 
A fundamental component of regenerative medicine is neovascularisation, which can be 
induced by promoting expression of angiogenic genes or targeted delivery of angiogenic 
growth factors and progenitor cells via engineered materials [2]. Although angiogenic 
protein therapy is the simplest and most straightforward approach for therapeutic 
angiogenesis, systemic administration of angiogenic factors is usually inefficient for 
reaching and/or maintaining the desired effective concentration at the site of interest due 
to rapid clearance or degradation of the delivered protein [3, 4]. Local administration (e.g. 
intracoronary, intramyocardial, or intracerebral injection) can better confine the 
distribution of the growth factors at the desired site; however, it requires expensive pumps 
or invasive surgeries [5]. Recently, biomimetic nanofibers have become auspicious 
candidates for delivering bioactive molecules, promoting a viable approach for local and 
controlled delivery of angiogenic factors to overcome the aforementioned challenges [6-
9]. 
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Neovessel formation and maturation requires the precise spatiotemporal presentation of 
both angiogenic and arteriogenic growth factors, so that endothelial tubes can form and 
recruit mural cells for subsequent investment of these nascent vessels with perivascular 
cell coverage, which is essential for stable blood vessel formation [10, 11]. FGF2 is one of 
the most extensively studied angiogenic factors in therapeutic angiogenesis [12-15]. 
However, clinical studies of FGF2 showed short-term induced angiogenesis as the new 
microvessels regressed over time and therefore did not confer long-term improvements in 
tissue perfusion [16, 17].  This is probably due to quick inactivation of FGF2 with bolus 
delivery, issues with patient selection and clinical trial end points [18], and the generation 
of immature and unstable blood vessels that regressed over time [9, 19]. Unlike FGF2, 
FGF9 is not angiogenic but it is known to target the mesenchyme [20], and to elevate 
neointimal smooth muscle cell proliferation after arterial injury [21]. Previously, the 
combination of FGF2 and FGF9 was shown to stimulate the formation of robust 
microvessels in Matrigel plugs that are more likely to persist compared with using only 
FGF2, and had the ability to respond to vasoactive agents [22]. In an ischemic hind limb 
mouse model, vessels formed in the presence of FGF9, delivered by means of an osmotic 
pump, were physiologically mature due to smooth muscle migration that wrapped the 
nascent microvessels resulting in their stabilization [22]. Notwithstanding this encouraging 
data, the use of an osmotic/infusion pump was accompanied by induced inflammation and 
is not clinically practical. Therefore, differential delivery of these growth factors in a pump-
free controlled and sustained manner remains to be an immediate need.  
In order to protect the growth factors from rapid clearance and to target neovessel 
maturation, the proposed strategy is to differentially deliver angiogenic (FGF2) and 
arteriogenic (FGF9) growth factors from a single electrospun biomaterial system. The 
differential delivery of this new combination of growth factors is promising; since FGF2 
will be released at a higher rate in the early stage inducing vessel formation, while FGF9 
will be released at a lower rate recruiting mural cells at a later stage prompting vessel 
stabilization. Different laboratories reported the release of two or more growth factors from 
composite biomaterial delivery systems where growth factors were loaded in different 
polymers and then combined to form a composite system [23-26]. It would be more 
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practical if differential release is attained from only one biomaterial; but this is challenging 
owing to the bulk degradation properties of most biomaterials. Vascular endothelial growth 
factor (VEGF) and platelet derived-growth factor (PDGF) has been a very popular 
combination and their dual delivery was widely investigated for blood vessel regeneration 
[8, 23, 27]; however, it has been reported that VEGF can act as a negative regulator for 
pericyte coverage of vascular sprouts through VEGFR-2 and consequently hinder vessel 
maturation under the conditions of PDGF-mediated angiogenesis [28]. 
In the current study, α-amino acid derived poly(ester amide) (PEA) electrospun fibers were 
proposed as a versatile controlled delivery vehicle for FGF2 and FGF9 to target 
neovascular maturation. PEAs derived from α-amino acids were previously shown to 
degrade by surface erosion mechanism and were biocompatible for tissue engineering 
applications [29-31]. Following a proof of principle study on the feasibility of 
biodegradable α-amino acid derived PEA nanofibers to deliver FGF9 [32],  the objectives 
of the current study were three-fold: (i) to dual load FGF2 and FGF9 into PEA fibers using 
a mixed blend and emulsion electrospinning technique and study the morphological 
properties and the in vitro dual release kinetics, (ii) to examine the in vitro angiogenesis 
capacities of the co-released FGF2 and FGF9 using endothelial tube formation and directed 
smooth muscle cell migration assays and, (iii) to evaluate the in vitro and in vivo 
inflammatory responses and potential cell niche recruitment.  
 
 Materials and Methods 
4.3.1 Materials 
The poly(ester amide) 8-Phe-4 was synthesized from L-phenylalanine, sebacoyl chloride, 
and 1,4-butanediol via interfacial polymerization and characterized as described in 
previous publications [29, 32]. Bovine serum albumin (BSA) and Fibronectin were 
purchased from Sigma-Aldrich Canada Co. (Oakville, ON). Micro BCA protein assay kit 
from Thermo Scientific Pierce Inc. (Rockford, IL). Recombinant human fibroblast growth 
factor-9 (FGF9), fibroblast growth factor-2 (FGF2), Platelet–derived growth factor BB 
(PDGF-BB), and human FGF9 and FGF2 DuoSet® ELISA kit were purchased from R&D 
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Systems Inc. (Minneapolis, MN). Vybrant® DiI and Hoechst 33342 dyes were from Life 
technologies (Burlington, ON). 
 
4.3.2 Cell Culture and Maintenance 
Primary human coronary artery smooth muscle cells (HCASMCs) were purchased from 
Lonza (Walkersville, MD) and cultured according to the supplier’s instructions in Medium 
231 and Smooth muscle growth supplement, complemented with 100 units/ml penicillin G 
sodium, 100 µg/ml streptomycin sulphate, and 2 mM L-glutamine (Invitrogen, Burlington, 
ON). Primary human coronary artery endothelial cells (HCAECs) were purchased from 
Lonza (Walkersville, MD) and cultured according to supplier’s instructions in EGM–MV 
Bullet Kit (Lonza, Walkersville, MD). THP-1 human monocytes (ATCC® TIB202™) were 
cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% FBS, and 1% 
penicillin/streptomycin (Invitrogen, Burlington, ON). All cultures were maintained in a 
humidified chamber at 37ºC containing 5% CO2. Cells were passaged every 7 days at a 
split ratio of 1:3 and used between passages 6 to 8. 
 
4.3.3 Dual-loading of PEA Fibers 
Dual loading of model protein BSA or FGF2, and FGF9 into the PEA fibers was carried 
out using a mixed technique of blend and emulsion electrospinning. The electrospinning 
parameters were established in previous studies [32]. Briefly, the PEA (8-Phe-4, average 
number MW between 30-40 kDa) was dissolved in chloroform and dimethyl sulfoxide 
(DMSO) at a ratio of (9:1). The polymer solution (0.5 mL) at 7.5% w/w concentration was 
electrospun using a high voltage DC power supply (ES30P, Gamma high voltage, USA) 
set to 20 kV and a 0.5 cc glass syringe (Becton, Dickinson and Co., Franklin Lakes, NJ) 
with a blunt–tip stainless steel spinneret (22 gauge) kept at 8 cm from the grounded 
collector (a rotating mandrel covered with aluminum foil rotating at 1000 rpm). The flow 
rate was kept at 0.1 mL/h using a syringe pump (KD101, KD scientific, Holliston, MA). 
BSA was dissolved in DMSO (1 µg/µL) and 100 µL were blended in the polymer solution. 
The same protocol was adopted for FGF2 loading, except for the lower initial loading (3.6 
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µg FGF2 per 100 µL of DMSO). Whereas, 30 µL of stock FGF9 solution in PBS (120 
ng/µL) were emulsified in the polymer solution by ultrasonication for 30 min in an ice 
bath. Similarly, Vybrant® DiI and Hoechst 33342 dyes were dual-loaded into the PEA 
fibers following the same procedure as FGF2 and FGF9, respectively. 
 
4.3.4 Characterization of PEA Electrospun Fibers 
Morphological analysis of the PEA fibers was performed using scanning electron 
microscopy and confocal laser scanning microscopy. For SEM, electrospun fibrous mat 
samples were sputter–coated with gold/palladium (K550X sputter coater, Emitech Ltd., 
UK) and scanned at a working distance of 10 mm and a constant accelerating voltage of 20 
kV, using S–3400N SEM (Hitachi, Japan). Vybrat® DiI and Hoechst dual loaded–PEA 
fibers were electrospun on No.1 coverslips for 30 s. Another No.1 coverslip was mounted 
over the coverslip containing the fibers and Trevigen® Fluorescence Mounting Medium 
(Trevigen INC., Gaithersburg, MD), and confocal images of Vybrat® DiI and Hoechst dual 
loaded–PEA fibers were captured with a Zeiss LSM 5 Duo confocal microscope equipped 
with nine laser lines and appropriate filters (Carl Zeiss, Toronto, ON). 
 
4.3.5 In vitro Release Study of Dual-loaded PEA Electrospun Fibers 
In vitro release studies of dual loaded PEA fibers were conducted as described previously 
for FGF9-loaded fibers [32]. Samples of 1 cm × 1 cm fibrous mats (with total amount of 4 
µg of BSA or 120 ng FGF2, and 120 ng FGF9/mat) were placed in a 24–well plate, and 
incubated with 1 mL of phosphate–buffered saline (PBS 50 mM, pH 7.4) under continuous 
agitation (100 strokes/min), in a thermostatically controlled micro–plate shaker (VWR 
International, Mississauga, ON) at 37°C. At pre–determined time intervals (Day 1, 3, 7, 
10, 14, and weekly thereafter), the supernatant was collected and replenished with an equal 
volume of fresh buffer. The supernatants were immediately frozen at −80°C until further 
measurements. The amount of BSA released was quantified by micro BCA protein assay 
kit, while the amount of FGF2 and FGF9 released was quantified by DuoSet® ELISA assay 
kit. The absorbance was measured using a micro–plate reader (UVM 340, Montreal 
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Biotech Inc., QC) and the unknown concentration was determined from a pre–constructed 
calibration curve and the percentage entrapment efficiency data. In order to correlate the 
in vitro release of the growth factors to the degradation rate of the PEA fibers; in vitro 
degradation of (1 cm × 1 cm) dual-loaded PEA mats was studied in PBS (50 mM, pH 7.4) 
at 37 °C for 3 months and evaluated by % mass loss and molecular weight analysis as 
previously described [32]. 
 
4.3.6  In vitro Angiogenesis Assays: Matrigel Tube Formation Assay 
Cell viability and metabolic activity of HCAECs on the 3D FGF2/FGF9-loaded PEA fibers 
was determined for 5 days by MTT assay following the manufacturer’s protocol 
(Vybrant®, Invitrogen, Burlington, ON, Canada). Unloaded fibers supplemented with 
soluble FGF2 and FGF9 was included as a positive control, and TCPS as a negative control. 
The experiments were conducted in triplicate as previously described [32]. Evaluation of 
in vitro tube formation using Matrigel assay was conducted by means of digital time–lapse 
video microscopy [33]. FGF2/FGF9–loaded fibers were allowed to release the growth 
factors in 35 mm culture dishes containing EC culture media (EGM-MV BulletKit, Lonza) 
for 7 days, in an incubator at 37°C and 5% CO2; 1 cm × 1 cm mats were utilized with total 
amount of 120 ng FGF2 and 120 ng FGF9/mat. 200–µL aliquots of the growth factor–
reduced Matrigel (VWR International, Mississauga, ON) were added per well to a 24-well 
plate and allowed to polymerize at 37°C for 30 min. HCAECs were trypsinized then 
suspended in a 250 µL media containing the released FGF2 and FGF9, and seeded at a 
density of 75,000 cells/well on Matrigel for 4 days. Images were acquired on an Olympus 
IX51 inverted microscope, using a 10× objective. The numbers of tube branch points were 
counted for two fields of view per well for different time points. Culture media incubated 
with unloaded PEA fibers served as a negative control, whereas media supplemented with 
FGF2 and FGF9, equivalent to that released at 7 days from the loaded fibers calculated 
from the in vitro release data, served as a positive control. Each treatment was performed 
in duplicate and three independent experiments were conducted.  
A modified tube formation assay was adopted in order to evaluate the interaction between 
endothelial cells and smooth muscle cells. To do this, HCAECs were infected with 30 µL 
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of Red Fluorescent Protein-Adenovirus (RFP-Adenovirus)/10 mm dish, while HCASMCs 
were infected with 100 µL of Green Fluorescent Protein-Adenovirus (GFP-
Adenovirus)/10 mm dish for 48 h. Tube formation assay protocol was followed as 
mentioned above and after 5 h incubation of RFP-expressing HCAECs on the Matrigel, 
GFP-expressing HCASMCs were added at 75,000 cells/well and incubated for further 24 h 
to evaluate SMC-interaction with the endothelial tubes using digital time–lapse video 
microscopy. Images were acquired, using a 10× objective, every 30 min for 24 h on Leica 
DMi8 inverted fluorescent microscope integrated with LAS-AF lite 2.6 software (Leica 
Microsystems Inc., Concord, ON). 
 
4.3.7 Directed Human Coronary Artery Smooth Muscle Cell Migration Assay 
Directed vascular smooth muscle cell migration was assessed by the transwell migration 
assay [34], using a Boyden–type microchemotaxis chamber (Neuro Probe, Inc., 
Gaithersburg, MD). HCASMCs were treated with FGF2/FGF9–loaded fibers for 7 days. 
HCASMCs were seeded onto 35 mm tissue culture dishes at cell density of 100,000 
cells/dish. The cells were allowed to attach for 1 h in the incubator, and then the 1 cm × 1 
cm FGF2/FGF9-loaded mat was suspended in the dish. The dual-loaded mats were allowed 
to release both FGF2 and FGF9 over 6 days (the SMC culture media containing 10% FBS 
was refreshed every other day). On Day 6, HCASMCs were starved for 24h by refreshing 
with serum–depleted media (containing 2% FBS). Polycarbonate membranes (Neuro 
Probe, Inc., Gaithersburg, MD) with 10 μm pores were pre–coated with 10µg/mL 
fibronectin and kept at 4°C overnight. Untreated or FGF2/FGF9–treated SMCs were 
washed in HBSS, trypsinized, and 25,000 cells re–suspended in 50 µL of serum–depleted 
media were added to the upper well of the Boyden chamber. The lower well of the chamber 
was filled with 28 µL of serum–depleted media with or without the chemotactic agent 
PDGF–BB. Migration was allowed to proceed for 6 h at 37°C under 5% CO2. SMCs 
remaining on the upper surface of the membrane (non-migrated cells) were mechanically 
removed using a wiper blade after dipping in PBS, and then the membrane was fixed in 
methanol (for 5 min) and stained with Harris’s hematoxylin (for 10 min). The number of 
cells that had migrated to the lower surface was determined by counting under high–power 
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microscopy (40× objective) in eight fields of view per well using an Olympus BX51 
inverted microscope. The experiments were performed in triplicate, and positive controls 
of soluble FGF2/FGF9–treated SMCs were included in the experiment. Moreover, this 
assay was used to test the bioactivity of the early released (cumulative released FGF2 and 
FGF9 between Day 1 and Day 13) and late released (cumulative released FGF2 and FGF9 
between Day 14 and Day 28) growth factors from the dual loaded PEA fibers, collected 
during the in vitro release study. 
 
4.3.8 In vitro Gene Expression of the Inflammatory Marker (Interleukin 8) 
Unloaded and FGF9/FGF2–loaded PEA fibers were affixed to the bottom of 12–well plate, 
sterilized by immersion in 70% ethanol (200 µL) for 30 min, and allowed to dry for one 
hour under germicidal UV light, before conditioning overnight in Hank’s balanced salt 
solution (HBSS, 200 µL; Invitrogen, Burlington, ON). THP-1 human monocytes were 
seeded onto the samples at an initial cell density of approximately 2 × 105 cells/well and 
cultured for three days in RPMI 1640 media containing 10% FBS, 1% 
penicillin/styptomycin and 2 mM L–glutamine, and maintained in a humidified incubator 
at 37 °C and 5% CO2.  Negative controls (TCPS), and positive controls of cells incubated 
with Escherichia coli lipopolysaccharide (E. coli LPS) at concentration of 5 µg/mL, were 
included in the experiment. After 72 h, the cells were collected and total RNA was 
extracted following TRIzol® reagent manufacturer’s protocol for suspended cells, and 
quantitative real-time Polymerase Chain Reaction (RT-qPCR) assay was employed to 
evaluate the RNA expression of the inflammatory marker interleukin 8 (IL-8) [35]. 
 
4.3.9 RNA Isolation and Quantitative Real–time PCR Analysis 
qPCR combined with reverve transcription was used to quantify messenger RNA (mRNA) 
expression of IL–8 in THP–1 cells seeded on control (TCPS), incubated with a positive 
control of E. coli lipopolysaccharide (E. coli LPS), unloaded PEA fibers, and FGF2/ FGF9–
loaded PEA fibers. Total RNA from the cells was extracted using TRIzol® reagent 
(Invitrogen, Burlington, ON) following the manufacturer’s protocol. Complementary DNA 
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(cDNA) was synthesized using 1µg of total RNA primed with oligo12–18 as described in 
SuperScript™ (Invitrogen, Burlington, ON). qPCR was conducted in 10 µl reaction 
volumes, using a CFX–96 Touch™ Real–time system C1000 Thermal Cycler (Bio–Rad, 
Mississauga, ON) and gene expressions of human IL–8 was then determined with 
SsoAdvanced™ SYBR® Green Supermix (Bio–Rad) according to the recommended 
protocol of the manufacturer. IL–8 forward primer: 
5′– CTTCCTGATTTCTGCAGCTCT–3′, reverse primer: 
5′– GTGGTCCACTCTCAATCACTC–3′, GAPDH forward primer: 
5′– GGTGGTCTCCTCTGACTTCAACA–3′, reverse primer: 
5′– GTTGCTGTAGCCAAATTCGTTGT–3′. Amplification entailed 40 cycles of: 
denaturation 95°C (15 s), annealing 55°C (30 s), and extension 65°C (30 s). The relative 
mRNA expression in the cells was normalized to the housekeeping gene glyceraldehyde–
3–phosphate dehydrogenase (GAPDH) with at least three repeats per experimental group 
and expressed as a relative ratio using the CFX ManagerTM 3.0 analysis software (Bio–
Rad, Mississauga, ON). 
 
4.3.10 Implantation into Subcutaneous and Tibialis Anterior Muscle Tissues 
The host response was evaluated by subcutaneously implanting unloaded and 
FGF2/FGF9–loaded PEA fibrous mats in 8–week old male C57BL/6J mice (The Jackson 
Laboratory, Bar Harbor, Maine). Experiments were conducted in accordance with the 
University of Western Ontario Animal Use Subcommittee. Briefly, samples of (4 mm × 
4 mm) PEA fibrous mats, unloaded or dual-loaded with FGF2 and FGF9 with total amount 
of 20 ng FGF2 and 20 ng FGF9/mat (n = 4), were surgically implanted into the dorsal 
subcutaneous tissue just superficial to the skeletal muscle and were harvested after 6 days. 
Prior to implantation, all the mats were sterilized under ultraviolet radiation for 4 h/each 
side. The mice were anaesthetized with Forane® (Baxter, Deerfield, IL) and their backs 
were shaved and wiped with alcohol. Two 6 mm horizontal full thickness skin incisions 
were made and the unloaded PEA mat was inserted in the left incision while the growth 
factor–loaded was implanted in the right incision and the incision was sutured using 6-0 
silk sutures to retain the mat in place. Sham surgery was included in the experiment to 
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serve as a control (n=2), where the incisions were made and sutured without the insertion 
of the PEA mats. The mice were sacrificed after 6 days, and the mats with the attached 
subcutaneous tissue were excised for histological examination. The tissue sections 
collected from the mice were fixed in 4% paraformaldehyde and dehydrated in 70% 
ethanol, then embedded in paraffin wax. Five micrometer–thick sections were cut with a 
rotary microtome (Leica 5 micron microtome) and Hematoxylin and Eosin (H&E) stained. 
H&E stained sections were examined with a Leica inverted light microscope (Leica 
Microsystems Inc., Concord, ON) and investigated for the infiltration of inflammatory 
cells. Follow-up experiments were carried out to evaluate the effect of FGF9 controlled 
delivery from the PEA fibers, at different initial loading concentrations (0, 20, 40, and 
80 ng/mat), on cell and tissue reaction upon implantation on the tibialis anterior muscle in 
the hind limb of B6 mice. Seven days after implantation of the FGF9-loaded PEA fibers 
onto the TA muscle, the mice were sacrificed and perfusion-fixed with 4% 
paraformaldehyde. The anterior calf muscle bundle was dehydrated in 70% ethanol, 
paraffin-embedded, and 5 μm sections were subjected to H&E staining and investigated 
for cell niche recruitment. 
 
4.3.11 Statistical Analysis 
Data is presented as mean ± SEM for experiments conducted in triplicate. Statistical 
analysis was conducted with one–way ANOVA followed by Tukey’s multiple comparison 
test using GraphPad Prism 4 software (GraphPad Software, Inc., San Diego, CA). 
Probability values less than 0.05 were considered statistically significant, unless otherwise 
stated. 
 
 Results 
4.4.1 Differential Release of FGF2 and FGF9 from Dual-loaded PEA Fibers 
In previous work, successful loading of FGF9 into PEA fibers was reported using blend 
and emulsion electrospinning techniques [32]. In the current study, a mixed blend and 
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emulsion electrospinning technique was proposed for dual loading of FGF2 and FGF9 into 
PEA fibers for therapeutic angiogenesis application. Confocal microscopy was employed 
to examine the dual loading strategy using two model fluorescent dyes. Red Vybrant® DiI 
was loaded using blend electrospinning, while blue Hoechst 33342 was loaded using 
emulsion electrospinning. The presence of blue vesicles along the red PEA fiber matrix 
(Figure 4-1 A) confirms the success of the dual loading strategy for the two model dyes 
using the mixed electrospinning technique.  
To demonstrate the controlled and differential release of bioactive molecules, a model 
protein (BSA, 4 µg/cm2) was dual-loaded with FGF9 (120 ng/cm2) into the PEA fibers. 
The morphology of the fibers was investigated using SEM, showing bead–free fibers with 
uniform fiber diameter distribution (Figure 4-1 B inset). The in vitro release of BSA and 
FGF9 was sustained over the 4 weeks study, in PBS (pH 7.4) at 37 °C, reaching 
approximately 76.9% and 25.3% for BSA and FGF9, respectively after 28 days (Figure 4-1 
B). In the same way, FGF2 (120 ng/cm2) and FGF9 (120 ng/cm2) were dual loaded into the 
PEA fibers. Similar sustained and differential release profiles were attained, which were 
fitted to a time–dependent power–law function [36]. The amount of FGF2 and FGF9 
released from the PEA fibers at the end of the 4–week study was approximately 28.5% and 
19.4%, respectively (Figure 4-1 C). Release studies for longer time periods (70 days), also 
showed a continuous controlled release of the growth factors reaching about 54.2% for 
FGF2 and 40.7% for FGF9 (Figure 4-1 C). In vitro degradation of the PEA fibers was 
previously investigated in PBS (pH 7.4) at 37°C for 4 weeks [32], and the fibrous mats 
maintained their structural integrity with total percentage mass loss of 21% after 28 days 
and without significant change in molecular weight. Longer degradation time-points 
showed 48% mass loss after 84 days while the molecular weight did not change appreciably 
indicating surface erosion degradation mechanism, which matches the in vitro release data 
(Figure 4-1 D-E). This supports the idea that biodegradable PEA fibers could be utilized in 
sustained co-delivery of FGF2 and FGF9 while attaining a differential release of the dual-
loaded growth factors. 
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Figure 4-1: Combined blend and emulsion electrospinning of growth factors facilitate 
differential release of the loaded proteins.  
(A) Confocal microscopy images of DiI and Hoechst dyes dual-loaded PEA fibers 
following the same mixed electrospinning protocol for growth factor loading. In vitro 
release study of (B) BSA and FGF9, (C) FGF2 and FGF9 dual-loaded PEA fibers, in PBS 
pH 7.4 at 37 °C for 4 weeks (n=3), with corresponding SEM insets, scale bar = 2 µm. In 
vitro degradation of PEA electrospun fibers in PBS (pH=7.4) at 37°C for 84 days. (D) 
Percentage mass loss of PEA fibers at different time points (n=3) and (E) molecular weight 
analysis using gel permeation chromatography. 
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4.4.2 Co-released FGF2 and FGF9 from PEA Fibers Enhanced Tube 
Formation and Directed SMC Migration 
The MTT metabolic activity assay showed that the number of attached human coronary 
artery endothelial cells (HCAECs) at Day 1 on both dual-loaded and unloaded fibres 
supplemented with FGF2 and FGF9 were fewer than those on the TCPS control (Figure 
4-2 ). However, those attached cells were viable for up to 5 days. Since visualization of 
tube formation on the 3D fibers/Matrigel via microscopy is not feasible due to the non-
transparency of the fibers, tube formation was investigated using a Matrigel tube formation 
assay employing HCAECs treated with media containing the co-released FGF2 and FGF9.  
 
Figure 4-2: Human coronary artery endothelial metabolic activity study on 3D 
FGF2/FGF9-loaded PEA fibers, unloaded fibers supplemented with soluble FGF2 
and FGF9 as a positive control, and TCPS as a negative control, for 5 days using MTT 
assay. Data represents mean ± SEM from three independent experiments.  
 
Endothelial tubes formed after 24 h of incubation were visualized by optical microscopy 
using a 10× objective (Figure 4-3). Quantitative representation of the data showed 
significant increase in the number of tubule branch points at 24 h in the case of co-released 
FGFs from the dual loaded PEA fibers compared to the negative control of culture media, 
whereas there was no significant difference from the positive control of soluble FGF2 and 
FGF9 (p < 0.05) as illustrated in Figure 4-3. Although the endothelial tubes would 
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eventually regress, the endothelial tubes treated with the co-released FGFs were holding 
better than the negative control after 4 days. This data supports that FGF2, being an 
angiogenic growth factor, stimulates tube formation and proposes potential benefits of 
strategically pairing it with FGF9. 
 
 
Figure 4-3: Co-released FGF2 and FGF9 from PEA fibers increased endothelial cell 
tube formation. Endothelial cells were treated with co-released FGFs or soluble FGF 
and cultured on growth factor–reduced Matrigel for 24 h.  
The tubule branch points were counted using an inverted microscope at 10× objective at 
different time points (n=3). Fresh culture media and growth factor-supplemented media 
were used as negative and positive controls, respectively. Scale bar = 200 µm, * indicates 
p < 0.05. 
 
A Boyden chamber transwell migration assay was employed to evaluate the directed 
migration of FGF2/FGF9 treated–human coronary artery smooth muscle cells 
(HCASMCs) to the chemotactic agent PDGF-BB. As illustrated in Figure 4-4 A-B, there 
was a significant increase in the number of migrated SMCs in the presence of PDGF-BB 
as a chemotactic agent compared to the group without PDGF-BB. This suggested that the 
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migration of FGF2/FGF9-treated SMCs was dominated by active directed migration to 
PDGF-BB instead of random migration. Also, the HCASMCs treated with the FGF2/FGF9 
dual-loaded fibers for 7 days showed a significant increase in directed migration compared 
to the negative control of untreated SMCs (p < 0.05). This indicated that FGF2/FG9 
treated-SMCs were more attracted to PDGF-BB.  
Ongoing research has shown the need of prolonged exposure of ischemic tissues to 
angiogenic and arteriogenic growth factors for the development of robust and sustained 
neovascularization [1, 18]. Since the ultimate goal is to use electrospun PEA fibers as a 
depot for FGF2 and FGF9 for ischemic tissue repair, the bioactivity of the co-released 
growth factors was evaluated over a period of 4 weeks. The data revealed that both early 
(released between Day 1 and Day 14) and late released (released between Day 15 and 
Day 28) growth factor–treated SMCs showed significant increase in the number of 
migrated cells compared to that of the negative control (p < 0.01); while the difference with 
their respective positive controls was not significant (p > 0.05; Figure 4-4 C-D). This 
observation suggests that the released growth factors from the PEA fibers will be available 
in a bioactive form for the period required to secure the stabilization and survival of the 
newly formed vessels. 
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Figure 4-4: Co-released FGF2 and FGF9 enhanced directed smooth muscle cell 
migration. 
(A and B) SMCs were incubated with FGF2/FGF9 dual loaded PEA fibers for 7 days and 
the treated SMCs that had migrated to PDGF-BB, after 6 h of incubation in Boyden 
chamber, were fixed, stained with Haematoxylin, and counted under high–power 
microscopy (40× objective) (n=3). Darker dots represent the membrane pores and lighter 
ones represent the nuclei. (C and D) Early co-released (Day 1 - Day 14; ER) and late co-
released (Day 15 - Day 28; LR) FGF2 and FGF9 from the PEA fibers from in vitro release 
study. Negative control of untreated SMCs and positive control of FGF2/FGF9–treated 
SMCs were included in the experiment. Scale bar = 100 µm, * indicates p < 0.05, ** 
indicates p < 0.01. 
 
Neovessel maturation requires the recruitment of mural cells and the subsequent wrapping 
of the nascent endothelial tubes with smooth muscle cells, which is essential for stable 
blood vessel formation.  Tube formation assay protocol was used to evaluate SMC 
interaction with the endothelial tubes using digital time–lapse video fluorescent 
microscopy. GFP-expressing HCASMCs were attracted to the RFP-expressing HCAEC 
tubes. After 24 h of incubation, SMCs invested the tube network of GFP-expressing 
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endothelial cells on Matrigel; the SMCs were wrapping the EC tubes resulting in thicker 
EC/SMC tubes when treated with the co-released FGF2 and FGF9 or soluble FGFs 
compared to the negative control (Figure 4-5). This demonstrates that co-released FGF2 
and FGF9 from the dual loaded PEA fibers can enhance the SMC-EC interaction and 
stabilize tube formation in vitro. 
 
 
Figure 4-5: Co-released FGF2 and FGF9 from dual-loaded PEA fibers stabilize tube 
formation.  
RFP-expressing endothelial cells were treated with co-released FGFs or soluble FGFs and 
cultured on growth factor–reduced Matrigel and incubated for 5 h, followed by culturing 
GFP-expressing smooth muscle cells at same cell density (75,000 cells/well) and further 
incubation for 24 h. Images were acquired, using a 10× objective, every 30 min for 24 h 
on Leica DMi8 inverted fluorescent microscope (n = 3). Negative control of fresh culture 
media and positive control of soluble growth factor-supplemented media were included in 
the experiment. Scale bar = 100 µm. 
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4.4.3 FGF2 and FGF9 Dual-loaded PEA Fibers did not Induce Inflammatory 
Responses 
The utility of FGF2/FGF9-dual loaded PEA fibers for therapeutic angiogenic application 
necessitates evaluating the induced inflammatory responses. For in vitro studies, human 
monocytes (THP-1) were incubated with unloaded and FGF2/FGF9 dual-loaded PEA 
fibers for 72 h, followed by evaluation of the RNA expression of a selected inflammatory 
marker (IL-8) using quantitative real time PCR assay. Figure 4-6 shows that both unloaded 
and dual-loaded PEA fibers did not show a significant difference in IL-8 gene expression 
compared with the negative control tissue culture polystyrene (TCPS). On the other hand, 
the E. coli LPS-treated human THP-1 monocytes (positive control) showed significant fold 
increase in gene expression of IL-8 (p < 0.01).  Therefore the lower RNA expression of 
IL- 8, a cytokine known for its leukocyte chemotactic activity,[37] may lead to a lesser 
leukocyte chemotaxis at the site of the PEA fibers implantation and this will lead to a 
reduced host immune response [35]. 
 
 
Figure 4-6: FGF2/FGF9-loaded PEA electrospun fibers did not induce an 
inflammatory response in vitro.  
The gene expression of the inflammatory marker IL-8 was evaluated using quantitative 
real-time PCR assay after incubation of the PEA fibrous mats with THP-1 monocytes for 
72 h (n = 3). Positive control of E. coli lipopolysaccharide was included in the experiment, 
** (p < 0.01). 
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The in vivo tissue response was evaluated by implanting unloaded and growth factor-
loaded PEA fibrous mat subcutaneously at the back of 8–week male B6 mice for 6 days, 
followed by the excision of the tissue and H&E staining for histological examination. H&E 
histological sections of the unloaded and the FGF2/FGF9-dual loaded PEA fibers 
demonstrated that the fibers did not fully degrade after 6 days of subcutaneous implantation 
and did not stimulate inflammatory cell infiltration or induce scar formation (Figure 4-7). 
Interestingly, in the case of the FGF2/FGF9-loaded PEA fibers; robust cell niche 
recruitment was observed around the mat. Furthermore, the damaged connective tissue 
started to regenerate around the fibers and there was higher population of cells resembling 
mesenchymal progenitor cells with increased ECM secretion around the FGF2/FGF9-dual 
loaded PEA fibrous mat. 
FGF9-loaded PEA fibers were implanted onto the tibialis anterior muscle of B6 mice for 7 
days in order to evaluate the effect of FGF9 controlled delivery from the PEA fibers, at 
different initial loading concentration (0, 120, 240, 480 ng/cm2), on cell niche recruitment 
in the context of hind limb muscles. Histological examination of the H&E sections 
demonstrated that the unloaded PEA fibrous mat implantation resulted in the encapsulation 
of inflammatory cells (Figure 4-8 A inset, red arrows). The induced inflammation was 
diffusive, but limited to the area surrounding the hypodermis and muscle surface. On the 
other hand, FGF9-loaded PEA fibrous mat implantation resulted in the amelioration of the 
inflammatory reaction (Figure 4-8 B-D). More importantly, FGF9 loading resulted in a 
dose-dependent expansion of mesenchymal progenitor-like cells that were organized in 
layers and deposited extracellular matrix surrounding the fibrous mat, but did not invade 
into the skin or the muscle. The highest tested initial FGF9-loading (480 ng/cm2) showed 
the most distinct expansion of the matrix-depositing cells and their higher level 
organization into layers (Figure 4-8 D inset, green brackets).  
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Figure 4-7: Subcutaneous implantation of FGF2/FGF9-loaded PEA electrospun 
fibers in B6 mice did not induce inflammatory cell infiltration.  
Sham surgery and negative control of unloaded PEA fibers were included in the experiment 
(n = 4). H&E histological sections were examined with a Leica inverted light microscope 
for inflammatory cell infiltration. Blue arrows are pointing to the PEA fibers and 
scale bar = 100 µm. 
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Figure 4-8: Controlled delivery of FGF9 from PEA fibrous mats resulted in a dose-
dependent expansion of mesenchymal progenitor-like cell layers and ECM 
deposition.  
FGF9-loaded PEA fibrous mats were implanted onto the TA muscle of B6 mice (n = 3), 
for 7 days to evaluate the effect of FGF9 controlled delivery (0, 120, 240, 480 ng/cm2) 
from the PEA fibers on cell niche recruitment (A-D), respectively. Blue arrows are pointing 
to the PEA fibrous mats with insets of higher magnification for the skin and muscle sides, 
red arrows point to the encapsulated inflammatory cells, and green bracket indicate the 
organized mesenchymal progenitor-like cell layers. Scale bar = 100 µm.  
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 Discussion 
The differential delivery of more than one growth factor from a single electrospun 
biomaterial has not been achieved as yet. The strategy developed in previous studies is to 
use a polymer blend, or multiple polymers each of which is loaded with one growth factor, 
and electrospun to form composite delivery systems [8, 38-40]. As an example, 
nanocomposite bone scaffolds, where FGF18-preloaded mesoporous bioactive glass 
nanospheres were incorporated within the FGF2-loaded core–shell electrospun 
polycaprolactone and poly(ethyleneoxide) fibers for bone regeneration were reported [39]. 
In another study, collagen-gelatin-hyaluronic acid composite delivery system 
incorporating three growth factors for wound healing was also reported [38]. In our study, 
a single α-amino acid-derived biomaterial that degrades by surface erosion [32, 41], was 
utilized for dual loading and differential release of FGF2 and FGF9 for therapeutic 
angiogenesis application. The in vitro release data showed sustained and differential 
delivery of FGF2 and FGF9 from the PEA electrospun fibers (Figure 4-1 C), which can 
positively influence the natural angiogenesis process; where the angiogenic growth factor 
(FGF2) plays an early role in the nascent tube formation stage, while the arteriogenic 
growth factor (FGF9) is needed later on in the process of vessel maturation and 
stabilization [42-44]. FGF2 was previously loaded into electrospun fibers using blend, 
emulsion and coaxial electrospinning [45-47], or through heparin immobilization onto 
polycaprolactone electrospun scaffolds [48]. However, the complexity of the angiogenesis 
process and the need for more than one growth factor for functional vascular tissue 
formation suggest the use of a differential and sustained delivery approach in order to 
pattern neovascular maturation.  
Angiogenesis is a multifaceted process that starts with the migration and proliferation of 
endothelial cells in response to angiogenic factors, followed by their remodeling into tubes. 
Subsequently,  the maturation of the newly formed vessels requires the recruitment of 
mural cells [49]. The in vitro angiogenesis assays data demonstrated that HCAECs treated 
with the co-released FGF2 and FGF9 from the FGF2/FGF9-dual loaded PEA fibers showed 
enhanced tube formation (Figure 4-2). Moreover, HCASMCs treated with FGF2/FGF9-
dual loaded fibers exhibited enhanced migration to PDGF-BB (Figure 4-3 A-B), which was 
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expected due to FGF2–induced increase in surface expression of α2β1 integrin [34] and 
FGF9-induced upregulation of platelet derived-growth factor receptor β (PDGFRβ) in 
human vascular SMCs, reported in previous work [22, 32, 50]. Furthermore, previously 
the upregulation of PDGFRβ have been shown to be mediated by sonic hedgehog-
PDGFRβ-dependent signaling [22]. Although the angiogenic synergism between FGF2 
and PDGF-BB has been reported [51], upregulating the receptor (PDGFRβ) via FGF9 is a 
more valid approach than delivering the PDGFRβ ligand. PDGF-BB delivery has been 
implicated to abolish the natural gradients of PDGF-BB required for SMC recruitment [52], 
whereas FGF9 delivery would not. Also, in the case of treating HCASMC/HCAEC co-
culture with the co-released FGF2 and FGF9, enhanced SMC-EC interaction was observed 
further stabilizing in vitro tube formation (Figure 4-4). In view of all this, dual delivery of 
FGF2 and FGF9 additively enhanced directed SMC migration and vessel stability.  
Biomaterials are implanted into a host either as delivery vehicles for delivering drugs and 
growth factors or as a tissue replacement. In either case, inflammatory response is 
inevitable. Although inflammation is associated with negative outcomes (e.g. fibrosis and 
implant rejection), some inflammatory reactions can promote biomaterial-tissue 
integration [53-55]. This is particularly beneficial if the implant is a tissue-engineered 
construct since the presence of macrophages could potentially yield a positive influence on 
stem cell recruitment and differentiation, allowing tissue integration, regeneration, and 
healing. Emerging data [53, 56] demonstrated that the positive influence of macrophages 
to be the result of a transition from a pro-inflammatory (M1) phenotype to a regulatory or 
anti-inflammatory M2 phenotype, thus promoting functional outcomes instead of scar 
tissue formation [56]. Scaffold surface topography appeared to be partially responsible for 
this phenotype transition since it affects monocyte/macrophage activation [57]. In addition 
to topography effects, implant integration to the host is facilitated by monocyte 
chemoattractant protein-1 (MCP-1). For instance, when vascular scaffolds fabricated from 
polyglycolic acid were seeded with bone marrow mononuclear cells (BMC) and implanted 
in mice, MCP-1 was secreted by BMC enhancing monocyte recruitment, which in turn 
recruited vascular progenitor cells [58]. Notwithstanding the above, inflammatory reaction 
to scaffolds loaded with growth factors/drugs is not generally desirable [24, 26, 59]. The 
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reason for this requirement is that inflammatory reaction often accelerates degradation of 
the scaffold implying rapid release of the payload instead of sustained release. Conversely, 
inflammatory reaction could also form a layer of fibrous capsule on the scaffold, which 
could potentially delay the release of the loaded growth factors. Induced inflammation and 
host response often preclude many synthetic biomaterials from growth factor-delivery 
applications [60]. This new class of α-amino acid-derived biodegradable PEAs, which are 
susceptible to either hydrolytic or enzymatic degradation [30, 61, 62], showed minimal 
induced inflammatory response in vitro (Figure 4-5). Moreover, subcutaneous implantation 
of the unloaded and the FGF2/FGF9-dual loaded PEA fibers in B6 mice did not induce 
significant inflammatory cell infiltration or scar formation (Figure 4-6). This was attributed 
to the naturally occurring degradation by-products that can be metabolized physiologically, 
limiting their potential inflammatory response and systemic toxicity [29]. Moreover, the 
degradation mechanism is governed by surface erosion [32], which limits the localized 
accumulation of acidic degradation by-products, thus avoiding significant pH decrease in 
the vicinity of the fibrous mat that usually results in inflammatory responses [63].  
In this study robust cell niche recruitment was observed around the FGF2/FGF9-loaded 
PEA fibers when implanted subcutaneously in mice. Cell niche recruitment is most likely 
attributed to FGF9 [22], and the H&E sections of the FGF9-loaded PEA fibers implanted 
onto the tibialis anterior muscle of B6 mice for 7 days confirmed that controlled delivery 
of FGF9 resulted in a dose-dependent recruitment of mesenchymal progenitor-like cells 
that were organized in layers and deposited extracellular matrix (Figure 4-7 A-D). FGF9 
has been reported to amplify mesenchymal progenitors in developing tissues [20, 64], and  
to maintain SMC progenitor cells in embryonic microvascular development [65]. FGF9 is 
expected to stimulate vascular maturation via recruitment of SMC progenitors to the 
nascent endothelial tubes and differentiation of some of this cell niche into contractile 
SMCs [22]. This highlights the role of the mesenchyme-targeting growth factor (FGF9) 
and its controlled delivery in the process of vascular maturation. In future studies, ischemic 
hindlimb mouse model will be utilized to examine the potential of FGF2/FGF9 dual-loaded 
PEA fibers to regenerate competent vasculature and to identify the recruited cell niche. 
Taken together, this data suggests the versatility of electrospun α-amino acid-derived PEA 
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fibers as promising candidates for the controlled delivery of angiogenic and arteriogenic 
growth factors with relevance to therapeutic angiogenesis and vascularization of in vitro 
tissue-engineered constructs. 
 
 Conclusions 
Differential presentation of angiogenic and arteriogenic growth factors is beneficial to 
induce stable neovascularization. In this study, it has been shown that FGF2/FGF9 dual-
loaded PEA fibers can be potential candidates for sustained and localized co-delivery of 
growth factors. The differentially released FGFs enhanced the directed SMC migration to 
PDGF-BB and stabilized tube formation in vitro. Particularly controlled delivery of FGF9 
in vivo resulted in a dose-dependent recruitment of mesenchymal progenitor-like cells that 
were organized in layers and deposited ECM. Altogether, with the absence of any induced 
inflammatory response in vitro or in vivo, FGF2/FGF9 dual-loaded PEA fibers can have a 
promising therapeutic angiogenesis application for treatment of ischemic vascular diseases.  
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Chapter 5  
5 In vivo Evaluation of FGF-loaded Electrospun Poly(ester amide) 
Fibers for Therapeutic Angiogenesis 
Overview: This chapter focuses on the in vivo angiogenesis evaluation of the FGF-loaded 
PEA fibers using the ex ovo chick choriallantoic membrane model coupled with power 
Doppler ultrasound imaging and the ischemic hindlimb mouse model followed by CatWalk 
assay and histological analysis. 
 Abstract 
Angiogenic protein therapies have shown great promise in preclinical studies; however, 
limited positive results have been achieved from clinical angiogenesis trials, in part, due to 
neovessel regression. A major limitation of angiogenic protein therapy is the rapid 
degradation and clearance from the site of delivery due to the short half-life of these 
exogenous angiogenic factors, resulting in a temporary therapeutic effect at the tissue of 
interest. Controlled delivery of angiogenic growth factors from polymeric-delivery system 
could overcome the aforementioned challenge. In this study, electrospun poly(ester amide) 
(PEA) fibers have been loaded with either fibroblast growth factor-9 (FGF9) alone or with 
FGF9 and fibroblast growth factor-2 (FGF2) to maintain a controlled release of these 
growth factors in a bioactive form over a period of months in an attempt to achieve vessel 
maturation and stabilization. FGF-loaded PEA fibers were evaluated using two in vivo 
models, the chick chorioallantoic membrane (CAM) model as a screening platform and the 
ischemic hindlimb mouse model as a pathological pre-clinical model. The CAM assay 
coupled with 3D power Doppler vascular quantification showed localized angiogenic 
effects at regions beneath the FGF-loaded fibrous mats. Moreover, the implantation of the 
FGF9-loaded PEA fibrous mats on the surface of infarcted tibialis anterior muscle resulted 
                                                 

 A version of this chapter is currently in preparation to be submitted for publication as “Somiraa S. Said, 
Hao Yin, Mai Elfarnawany, Zengxuan Nong, Caroline O’Neil, Hon Leong, James Lacefield, Kibret 
Mequanint and Geoffrey Pickering”.   
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in an enhanced skeletal muscle regeneration and increased abundance of mural-wrapped 
microvessels compared with the unloaded fibers control group as demonstrated by 
histological analysis. This supports the hypothesis that controlled delivery of FGF9 from 
electrospun PEA fibers enhances the assembly of functional and stable microvessels.  
 
Key words: Angiogenic protein therapy; Poly(ester amide) electrospun fibers; Fibroblast 
growth factor-2; Fibroblast growth factor-9; CAM angiogenesis assay; Ischemic hindlimb 
mouse model. 
 
 Introduction 
In vitro angiogenesis assays are quantitative and efficient but their findings should be 
confirmed by in vivo models. In vivo assays are more laborious and challenging to 
quantitate; however, the formation of functional blood vessels involves complex 
interactions between multiple cell types, which necessitates preclinical testing. Simple 
animal models such as the chick chorioallantoic membrane (CAM) [1, 2], zebra fish 
embryo [3, 4] and rabbit corneal pocket [5] have been widely used to assess angiogenesis 
in vivo. Clinically-relevant animal models have also been used to demonstrate the potential 
of angiogenic therapies for myocardial and peripheral ischemia [6]. Myocardial ischemia 
is most commonly induced by ligation of the anterior descending branch of the left 
coronary artery [7] or by placing ameroid constrictors around the coronary artery [8]. 
Hindlimb ischemia is typically induced by ligation and/or excision of the common femoral 
artery or iliac artery [9, 10], with or without accompanying ligation of collateral vessels. 
In animal models, histological demonstration of enhanced angiogenesis and tissue healing 
or perfusion after an acute arterial occlusion is a common preclinical endpoint [6]; 
however, the functionality of the newly formed vessels and the restoration of the ischemic 
muscle function should also be considered in animal models. The most studied growth 
factors in animal models for therapeutic angiogenesis are vascular endothelial growth 
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factor (VEGF), fibroblast growth factor-2 (FGF2) and platelet-derived growth factor 
(PDGF)-BB [6]. 
In this chapter, the chick CAM model is proposed as an in vivo angiogenesis assay to 
evaluate the developed FGF2/FGF9 dual loaded PEA fibrous mats. Since the chick embryo 
is a living system, this model provides a simplistic physiological system for in vivo analysis 
than the in vitro assays. The CAM is the extraembryonic membrane that lies directly under 
the egg shell of all avian species allowing for gas and nutrient exchange [11, 12]. It is 
highly vascular, readily accessible, relatively immunotolerant and inexpensive [13]. Large 
numbers of eggs can be prepared for the CAM assay in a relatively short time and the 
results can be quantified rapidly with minimal equipment allowing for large-scale 
screening. This system has been used for the study of vascular development and 
angiogenesis [14]. Because of its rapid vascular growth, many pro- and anti-angiogenic 
agents have been tested by quantifying the morphological responses of the CAM 
vasculature [15]. Moreover, it is possible to test controlled release delivery systems via 
local application on the CAM surface [1], and the lack of excretion allows to preserve the 
concentration of bioactive reagents in the circulation for extended period of time [13]. 
Power Doppler ultrasound imaging of the CAM allows for better interpretation of vascular 
remodeling in the local microenvironment of the angiogenic therapy. 
Since a single in vivo model is usually inadequate to fully investigate the process of 
angiogenesis, a more clinically relevant model, the ischemic hindlimb mouse model, was 
considered to further investigate the potential of FGF9-loaded electrospun PEA fibers to 
induce the formation of mature vasculature in ischemic conditions. Ischemic conditions 
usually creates high FGF2 gradient in the affected tissue [16], which minimizes the need 
for FGF2 controlled delivery. If a sufficient amount of FGF9 is delivered to the ischemic 
tissue, it may act in the local microenvironment where most of the growth factors, their 
receptors and signaling pathways necessary for the vascular remodeling are already present 
[17-19]; therefore, it will not need to initiate and maintain the whole complicated process 
of angiogenesis. Hence, the study focused on the local and controlled delivery of FGF9 
and testing the effects of FGF9-loaded PEA fibrous mats on tissue regeneration and new 
microvessel stabilization using the ischemic hindlimb mouse model. 
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In the current study, FGF-loaded PEA fibrous mats were studied using two in vivo models; 
the CAM model coupled with power Doppler ultrasound imaging to study localized 
angiogenesis, and the ischemic hindlimb model followed by quantitative CatWalk gait 
assay and histological analysis including H&E and double immunofluorescent staining to 
study tissue regeneration and mature neovessel formation.  
 
 Material and Methods 
5.3.1 Materials 
The poly(ester amide) 8-Phe-4 was synthesized from L-phenylalanine, sebacoyl chloride, 
and 1,4-butanediol through interfacial polymerization and characterized as described in 
previous publications [20, 21]. Recombinant human FGF9 and FGF2 were purchased from 
R&D Systems, Inc. (Minneapolis, MN). Hank’s balanced salt solution was purchased from 
Invitrogen Canada (Burlington, ON). The FGF-loaded PEA fibers were fabricated by the 
electrospinning technique and characterized as previously reported [21, 22].  
 
5.3.2 Chick Chorioallantoic Membrane (CAM) as an Angiogenesis Screening 
Platform for FGF2/FGF9 Dual-loaded PEA Fibrous Mats 
Fertilized White Leghorn chicken eggs were obtained from McKinley Hatchery (St 
Mary’s, ON, Canada). Eggs were incubated for three days at 38 °C and 80% relative 
humidity (RH) in a rotating hatcher (Sportsman hatcher, Berry Hill, ON). On Day 4 post-
fertilization, the eggs were removed from the hatcher and were cracked gently using a 
blade. The embryos were transferred into weighing boats with a plastic cover, an ex ovo 
culture system, to expose the CAM and make it accessible for imaging (Figure 5-1). The 
ex ovo culture protocol is previously described [23]. The shell-less chick embryos were 
returned to the incubator (38 °C, ~80% RH) till Day 10. 
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Figure 5-1: The ex ovo CAM cultivation protocol steps. 
(a) Gentle cracking of the egg using a blade, (b) transferring the contents into weighing 
boats and (c) covering with a plastic cover. Adapted from [15]. 
 
5.3.2.1 Experimental Design 
On Day 10, the CAMs were retrieved from the incubator to start the study. Four test 
conditions were examined to study the vascular density increase of the full CAM surface: 
soluble growth factors on KimwipeTM (1 cm × 1 cm) (10 µL FGF2 solution and 10 µL 
FGF9 solution in PBS at a concentration of 1 ng/µL), unloaded PEA fibers (1 cm × 1 cm), 
FGF2/FGF9 dual-loaded PEA fibers (1 cm × 1 cm), and control (no fibers). The samples 
were conditioned overnight in Hank's balanced salt solution (HBSS) before placing on the 
CAM. To maintain the temperature during the experiment, the chick embryos were placed 
over a warming pad (Gaymar Industries, Inc., Orchard Park, NY) set to 40 °C. A total of 3 
CAMs were used for each condition and the experiment was repeated three times. The 
CAMs were supplemented with 50 µL of HBSS at pre-determined time intervals to keep 
the mats moist, which could assist in the process of growth factor diffusion. Each CAM 
was digitally photographed at Day 0, 2, 5, and 8, and then imaged using power Doppler 
ultrasound at Day 8 when the vascular network of the CAM fully matures as previously 
reported [12]. The embryos were allowed to stabilize for 2-5 minutes prior to image 
acquisition. All procedures complied with the guidelines of the Canadian Council on 
Animal Care. 
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5.3.2.2 Image Acquisition  
Digital photographs (2448 × 2448 pixels) of the full CAM surface were captured using a 
Samsung Galaxy S6 camera (16 MP, Samsung Electronics Canada Inc., Mississauga, ON). 
The phone was placed on a custom made stage designed to keep the phone parallel to and 
at a fixed height from the CAM surface. Three dimensional (3D) power Doppler images of 
the CAM vasculature were acquired using a 40 MHz linear array transducer (MS550D, 
FUJIFILM VisualSonics, Inc., Toronto, Canada) and Vevo 2100 high-frequency imaging 
system (FUJIFILM VisualSonics, Inc) setup to the digital RF mode. The settings were 
fixed throughout the study (frequency, 40 MHz; power, 100%; B-mode gain, 22 dB; power 
Doppler gain, 12 dB; dynamic range, 65 dB; pulse repetition frequency, 1 kHz; wall-filter, 
low). Warmed Aquasonic 100 ultrasound transducer gel (Parker Laboratories, Inc., NJ, 
USA) was applied to the transducer face and used for coupling between the transducer and 
the CAM surface. Few drops of warmed saline were applied to the CAM surface at the 
CAM-transducer contact area as a lubricant to prevent sticking of the CAM surface to the 
transducer gel. Imaged regions of interest (ROI) were set to (lateral × axial × elevation = 
13.88 × 10.00 × 14.10 mm with an elevation spacing between B-mode planes of 0.0762 
mm) and were selected to include clear arterial and venular branching patterns far enough 
from the embryo body to reduce reflection and motion artifacts. The 3D power Doppler 
images were exported in the quadrature demodulated (IQ). 
 
5.3.2.3 Digital Image Pre-processing  
Using the full view of the CAM surface, the scale was calibrated using the reference 
dimensions of the plastic weighing boats carrying the embryos (89 mm × 89 mm). Images 
were then cropped keeping only the region showing the vascular network of the CAM using 
the polygon selection tool in Fiji software (NIH, Maryland, USA) [24]. The percentage 
vascular density, the number of pixels representing vessels (white pixels) divided by the 
total number of pixels in the ROI × 100, was automatically calculated from the cropped 
images using Vessel Analysis plugin for Fiji software developed by Nivetha Govindaraju 
and Mai Elfarnawany [URL link to the page: http://imagej.net/Vessel_Analysis]. The 
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plugin applies a series of filters, noise reduction, thresholding and binarization functions 
to the ROIs prior to estimating the vascular density. The pre-processing steps and a sample 
of the final binary image are shown in Figure 5-2.  
 
 
Figure 5-2: Steps of digital image pre-processing to produce the final binary CAM 
image used in percentage vascular density analysis. 
 
5.3.2.4 Power Doppler Processing and Vascular Quantification 
Power Doppler quadrature demodulated (IQ) data was processed using software 
implemented in MATLAB R2013a (The MathWorks, Inc., MA, USA) to apply the two-
stage method for power Doppler microvascular angiography developed by Elfarnawany et 
al. [25, 26]. In the first stage, the wall filter cut-off frequency is spatially tuned for local 
variations in the processed image using the wall filter selection curve (WFSC) method [27]. 
The 3D power Doppler volume of the vascular network is reconstructed from the spatially 
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tuned images. In the second stage, a 3D vessel tree is extracted from the power Doppler 
volume by applying a 3D skeleonization algorithm followed by reconstruction of the full 
diameters of the vessels along the skeletons. To retain the intensity values of the power 
Doppler signal in the final image, the original 3D power Doppler volume is masked using 
the 3D vessel tree resulting in a power-weighted 3D vessel tree with reduced color voxel 
artifacts.  
 
The resulting 3D power Doppler vessel tree was quantified using the three standard power 
Doppler angiography metrics [28]: 
𝑉𝑎𝑠𝑐𝑢𝑙𝑎𝑟𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑖𝑛𝑑𝑒𝑥 (𝑉𝐼) =  
𝑐𝑜𝑙𝑜𝑟 𝑣𝑜𝑥𝑒𝑙𝑠
𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑥𝑒𝑙𝑠 𝑖𝑛 𝑅𝑂𝐼
 
𝐹𝑙𝑜𝑤 𝑖𝑛𝑑𝑒𝑥 (𝐹𝐼) =  
𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑐𝑜𝑙𝑜𝑟 𝑣𝑜𝑥𝑒𝑙𝑠
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑜𝑙𝑜𝑟𝑒𝑑 𝑣𝑜𝑥𝑒𝑙𝑠 (𝑚𝑚3)
 
𝑉𝑎𝑠𝑐𝑢𝑙𝑎𝑟𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑓𝑙𝑜𝑤 𝑖𝑛𝑑𝑒𝑥 (𝑉𝐹𝐼) =  
𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑐𝑜𝑙𝑜𝑟 𝑣𝑜𝑥𝑒𝑙𝑠
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑥𝑒𝑙𝑠 𝑖𝑛 𝑅𝑂𝐼 (𝑚𝑚3) 
 
 
where, VI measures the proportion of color voxels in the ROI, representing the amount of 
moving blood in the tissue, FI, the mean power signal of blood flow, represents the 
intensity of flow at the time of acquisition and VFI is a combination of vascularization and 
flow indices representing both blood flow and vascularization. The denominators of the FI 
and VFI metrics were modified by Elfarnawany et al. [26] from their original definition  
by replacing the number of voxels by the total volume occupied by these voxels in mm3 to 
compensate for longitudinal variations in the voxel size when using differently sized 
Doppler ROIs at different time points. These three vascularization measurements were 
calculated from the 3D power Doppler volumes for the four test conditions and compared 
to give an idea about the quality of the induced vasculature in the localized volume of the 
CAM underneath the fibrous mats. 
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5.3.3 Ischemic Hindlimb Mouse Model: In vivo Angiogenesis Assay for FGF9-
loaded PEA Fibers 
5.3.3.1 Experimental Design  
 
Male C57BL6/J mice 3 month of age were anesthetized by Isoflurane inhalation (Forane®, 
Baxter, Deerfield, IL) and hindlimb ischemia was induced as described in Figure 5-3 [9]. 
Briefly, the right femoral artery was exposed through an incision in the skin overlying the 
middle portion of the hind limb. The femoral artery was ligated above and below the 
profunda femoris branch using 6-0 silk sutures. The artery and vein with all side-branches 
were dissected, avoiding the femoral nerve, and the intervening 5–6 mm portion of artery 
was excised. Nine mice were used per group (FGF9-loaded vs unloaded fibers group). 
FGF9-loaded fibrous mats (~2 ng release per cm2 per day) and control of unloaded fibrous 
mats were implanted subcutaneously on the calf region, as a layer of 5 mm × 7 mm sheet, 
at the interface between the skin and tibialis anterior (TA) muscle. The fibrous mat covered 
the lower 2/3 of the TA muscle surface. The fibers were pre-implanted 3 days before 
hindlimb ischemia was induced. Seven days post-ischemia induction, mice were subjected 
to CatWalk gait analysis and then sacrificed and the calf tissues were harvested for 
histological analysis. All animal procedures were approved by the Council on Animal Care 
of the University of Western Ontario and were in accordance with the guidelines of the 
Canadian Council on Animal Care. 
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Figure 5-3: Surgical procedure for induction of hindlimb ischemia by femoral 
artery ligation in C57BL6/J male mice.  
Ventral aspect of right mouse thigh and upper hind limb after hair removal (a). Surgical 
skin incision (5 mm) beginning from the groin skinfold following and immediately lateral 
to the vascular contours visible through the skin (b). Blunt dissection and separation of the 
femoral artery and vein (c). Insertion of surgical thread underneath the femoral artery (d). 
Faint appearance of collaterals from the deep branch (arrowhead). Ligation of the femoral 
artery distal to the origin of the deep branch by a triple surgical knot (e). Blood flow is 
diverted to collaterals (dashed white arrow) and collateral arteries now appear prominent 
(compare arrowheads from d and e). Over-and-over skin suture (f). Scale bars = 2 mm. 
Used with permission from Macmillan Publishers Limited [9] © 2009. 
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5.3.3.2 CatWalk Automated Quantitative Gait Analysis 
CatWalk assay is a highly sensitive tool to assess gait and locomotion. The mouse traverses 
a glass plate voluntarily, and its footprints are captured. It visualizes the prints and 
calculates statistics related to print dimensions and the time and distance relationships 
between paw falls. CatWalk assay usually used in neurological research, but it has been 
used in this study to assess functional recovery of the ischemic hindlimb by determining 
the extent to which the injured limb was used for walking [29]. The mice were subjected 
to the CatWalk assay at Day 7, and the average of at least 3 runs across the glass plate of 
an enclosed walkway was used for further analysis by the Noldus 7.1 software (Noldus 
Information Technology Inc., Leesburg, VA). In the CatWalk system, LED light from a 
fluorescent lamp illuminates the inside of the glass floor plate of the walkway. Light is 
reflected downward at sites of paw contact with the upper surface of the glass plate, the 
intensity of which is proportional to the relative force being exerted by the paw. Light 
reflection was recorded with a video camera and analyzed to determine the print intensity, 
print area and duty cycle for comparison between the FGF9-loaded fibers and the unloaded 
fibers-treated mice groups. Print intensity is expressed as the mean brightness of all pixels 
of the print at maximum contact, the print area (mm2) is the surface area (in pixels) of the 
complete print, while the duty cycle (%) expresses the stance duration as a percentage of 
the duration step cycle including stands and swings. All values were normalized to the 
contralateral healthy (left) hindlimb and expressed as mean percentage.  
 
5.3.3.3 Histological Analysis 
The mice were sacrificed at Day 7 and perfusion-fixed with 4% paraformaldehyde (PFA). 
The whole hindlimbs were immersed in 4% PFA overnight. The anterior calf muscle 
bundle was isolated and fixed with 4% PFA for another 24 h before paraffin embedding. 
Muscle tissues, including TA, extensor digitorum longus (EDL) and palmaris longus (PL) 
muscles, were cross-sectioned at 5 μm thickness and subjected to hematoxylin and eosin 
(H&E) staining, or double-immunostained using biotinylated rat anti-mouse CD31 
antibody (Clone MEC13.3, BD Biosciences) and mouse anti-smooth muscle α-actin (SM 
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α-actin) antibody conjugated with alkaline phosphatase (Clone 1A4, Sigma), or rat anti-
mouse endomucin antibody (V.7C7, Santa Cruz) and rabbit anti-NG2 Chondroitin sulfate 
proteoglycan antibody (AB5320, EMD Millipore). Images were acquired on an Olympus 
IX51 inverted microscope equipped with North Eclipse software, using 20× and 40× 
objective. Due to inter-individual variation in muscle regeneration at Day 7, the 
histological comparison was limited to regions with similar degree of myofiber 
regeneration in the TA muscle. Five ROIs per section were analyzed qualitatively for H&E 
stained sections in terms of induced inflammation and the degree of regeneration of the 
infarcted TA muscle, and quantitatively for double-immunofluorescent stained sections by 
counting mural-covered microvessels (SM α-actin or NG2 positive microvessels) using 
ImageJ software.  
 
5.3.4 Statistical Analysis 
Data is presented as mean ± SEM for experiments conducted in triplicate. Statistical 
analysis was conducted with t-test or one-way ANOVA followed by Tukey’s multiple 
comparison test using GraphPad Prism 4 software (GraphPad Software, Inc., CA, USA). 
Probability values less than 0.05 were considered statistically significant, unless otherwise 
was specified. 
 
 Results and Discussion 
 
5.4.1 FGF2/FGF9 Dual-loaded PEA Fibers Induced Localized Angiogenesis in 
CAM Model 
 
5.4.1.1 Analysis of Vascular Density of the Full CAM Surface 
Figure 5-4 A shows the digital photographs (2448 × 2448 pixels) of the full CAM surface, 
captured using a Samsung Galaxy S6 camera and the images were processed using ImageJ 
software, following the previously described scheme (Figure 5-2). The percentage increase 
in vascular density of the CAM at each time-point was calculated by subtracting the initial 
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vascular density at Day 0 for each chick embryo from the vascular density at Day 2, 5, and 
8. The digital images showed a qualitative increase in vascular density of the CAMs treated 
with the 4 test conditions with time; however, there was no significant difference in the 
vascular density of the CAM between the 4 test conditions at Day 2, 5, and 8 (Figure 5-4 
B). The ex ovo CAM model had some limitations in detecting a significant increase in 
vascular density of the full CAM vasculature due to its rapid vascular growth that outpaced 
the controlled and relatively slow release of FGF2 and FGF9 from the PEA fibers. 
Furthermore, the released amount of growth factors from the fibers might not have reached 
the effective therapeutic dose to induce significant angiogenesis in the full CAM surface.  
 
 
 
Figure 5-4: The effect of FGF2/FGF9 dual-loaded PEA fibers on CAM vasculature.  
(A) Digital photographs of the full CAM surface, (B) Percentage increase in vascular 
density of the full CAM vascular density calculated at pre-determined time intervals (Day 
2, 5, and 8) for the control (no fibers), CAMs treated with soluble growth factor, unloaded 
PEA fibers, and FGF2/FGF9 dual-loaded PEA fibers with respect to Day 0. Scale bar = 10 
mm, (n=3).  
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5.4.1.2 Vascular Quantification Using 3D Power Doppler Volumes of the CAM  
The 2D power Doppler images showed an increase in the CAM thickness in case of the 
soluble GFs on KimwipeTM group with the soluble growth factors, unloaded PEA fibers, 
and the FGF2/FGF9 dual-loaded PEA fibers compared to the control (no fibers), which 
might be due to induced inflammation of the CAM surface, as indicated by the increased 
thickness of the CAM tissue (Figure 5-5). Nevertheless, it is worth noting that the induced 
inflammation due to the PEA fibers was much less than that induced in the soluble GFs on 
KimwipeTM group (Kimwipe was used in the study to confine the GF solution and provide 
comparable conditions to the PEA fibrous mat). Furthermore, the PEA fibers were more 
flexible and adapting with the increased vascularity of the CAM surface with time. 
 
 
Figure 5-5: The power Doppler 2D images of the control (no fibers), CAMs treated 
with soluble growth factor, unloaded PEA fibers, and FGF2/FGF9 dual-loaded PEA 
fibers, acquired at Day 8. 
The power Doppler 2D images show transverse sections of the CAM tissue represented 
in gray scale and the vessels represented in red. 
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Moreover, the fibers did not interrupt the vascular network of the CAM underneath, which 
resulted in slight bending of the horizontal vessel network when compared to the control 
as shown in the power Doppler 3D volumes (Figure 5-6). In addition, the 3D volumes 
showed the formation of smaller vessels near the CAM surface in case of the dual-loaded 
PEA fibers and soluble GFs on KimwipeTM treated CAMs, which were not observed in 
case of the unloaded PEA fibers treated and the control CAMs (Figure 5-6). This suggests 
a localized angiogenic effect at the interface between the fibrous mat and the CAM surface.  
 
 
Figure 5-6: The power Doppler 3D vessel trees resulting from applying the two-stage 
signal processing method for power Doppler angiorgraphy [26]. 
3D volumes for ROIs (lateral × axial × elevation= 13.88 × 10.00 × 14.10 mm with elevation 
spacing between B-mode planes of 0.0762 mm) of the control, and CAMs treated with 
soluble growth factor, unloaded PEA fibers, and FGF2/FGF9 dual-loaded PEA fibers, 
acquired at Day 8.  
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Furthermore, vascular quantification of the 3D power Doppler volumes was carried out 
using modified Pairleitner et al. equations [28]. Vascularization and flow metrics for VI, 
VFI, and FI (Figure 5-7) indicated a statistically significant increase in vascularization and 
vascularization flow indices (VI and VFI) for the dual-loaded PEA fibers group versus the 
unloaded PEA fibers group, which might indicate the assembly of a better quality 
microvessels and increased amount of moving blood in the CAM underneath the fibrous 
mat owing to the controlled release of FGF2 and FGF9. 
 
 
Figure 5-7: Vascular quantification of the power Doppler 3D volumes of the control, 
and CAMs treated with soluble growth factor, unloaded PEA fibers, and FGF2/FGF9 
dual-loaded PEA fibers, acquired at Day 8 (n=3), (* p < 0.05, *** p < 0.0001). 
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5.4.2 Controlled Release of FGF9 from PEA Fibers Stimulated Stable 
Microvessel Formation in Ischemic Hindlimb Mouse model  
In order to assess whether the controlled release of FGF9 from PEA fibers promotes 
neovessel formation and maturation in ischemic conditions, FGF9-loaded PEA fibrous 
mats were implanted directly onto the TA muscle of B6 mice subjected to femoral artery 
ligation 3 days post-implantation. 
 
5.4.2.1 Functional Recovery of the Ischemic Hindlimb upon Implantation of 
FGF9-loaded PEA Fibrous Mats   
Functional recovery of the ischemic hindlimb by the controlled delivery of FGF9 was 
assessed using CatWalk analysis of mice traversing an illuminated glass plate and its foot 
prints were recorded. At Day 7 post-ischemia, there was no statistically significant 
difference (p > 0.05) between the print intensity, print area and duty cycle of the injured 
hindlimbs treated with FGF9-loaded fibers compared with those treated with unloaded 
PEA fibers in terms of usage of the injured limb for weight bearing (Figure 5-8). Detection 
of significant differences in terms of functional recovery of the injured limbs at Day 7 post-
ischemia might be too early, so longer time-point studies (28 days) are proposed in order 
to evaluate the effect of controlled delivery of FGF9 on reversing ischemia and restoration 
of function. 
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Figure 5-8: CatWalk automated quantitative gait analysis for mice treated with 
unloaded and FGF9-loaded PEA fibrous mats.  
The values for (A) the print intensity, (B) print area and (C) duty cycle for the ischemic 
limb at Day 7, were normalized to that of the contralateral healthy limb and expressed as 
mean%, (n = 9) and each dot represents one mouse. 
 
5.4.2.2 Histological Analysis of the TA Muscle Using H&E and Double- 
immunofluorescent Staining  
Histological analysis of tissues harvested 7 days post-ischemia showed enhanced 
regeneration of the infarcted TA muscle and increased angiogenesis with reduced 
inflammation and minimal tissue necrosis as illustrated by the H&E photomicrographs 
(Figure 5-9).  Moreover, a reduced presence of interstitial adipocytes in the regenerating 
skeletal muscle zone was observed for the injured hindlimbs treated with FGF9-loaded 
fibers.  
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Figure 5-9: H&E staining of the histological sections of the TA muscle.  
Photomicrographs of the TA muscle (20× objective) harvested at Day 7, (A) without 
infarction and after implantation of (B) unloaded PEA fibers and (C) FGF9-loaded PEA 
fibers 3 days prior to infarction (scale bar = 100 µm). 
 
Fluorescence microscopy images of the TA muscle double-immunolabeled for CD31 and 
SM α-actin showed no difference in the number of CD31-positive microvessels between 
the TA muscles treated with unloaded and FGF9-loaded fibers (Figure 5-10). However, 
controlled delivery of FGF9 resulted in a statistically significant increase (p < 0.05) in the 
proportion of microvessels invested by SM α-actin–containing mural cells (Figure 5-10 
B&D).  
 
NG2 is a pericyte cell marker; it is expressed in nascent microvessels by vascular pericytes 
[30]. While, endomucin is a sialomucin or CD164 that is specifically expressed on the 
endothelium of adult mice during development of the vascular system [31]. Using NG2 as 
mural cell marker could give us further insights into the recruitment of mural cells by FGF9 
and their investment of the neomicrovessels. Results from the NG2/endomucin double 
immunostaining of the TA muscle were similar to that observed from the CD31/SM α-
actin double immunostaining, showing a statistically significant increase (p < 0.01) in the 
proportion of microvessels invested by NG2–containing mural cells, which confirms the 
enhanced mural cell wrapping of the microvessels due to the controlled release of the FGF9 
(Figure 5-11). 
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Figure 5-10: CD31/SM α-actin double immunostaining of histological sections of the 
TA muscle at Day 7 and quantitative estimation of SM α-actin+ microvessels at the 
skin side.   
Fluorescence microscope images of TA muscle (40× objective) harvested 7 days after 
implantation of (A) unloaded PEA fibers and (B) FGF9-loaded PEA fibers, double 
immunolabeled for CD31 (red) and SM α-actin (green). Quantitative estimation of (C) the 
number of CD31+ arteriole-like microvessels at the skin side per high power field (40× 
objective), and (D) percentage of SM α-actin+ microvessels normalized to the total number 
of CD31+ microvessels per field (n = 9). Scale bar = 50 µm and arrows are pointing to 
CD31/SM α-actin+ microvessels (* p < 0.05).  
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Figure 5-11: Endomucin/NG2 double immunostaining of histological sections of the 
TA muscle at Day 7 and quantitative estimation of NG2+ microvessels at the skin side.  
Fluorescence microscope images of TA muscle (40× objective) harvested 7 days after 
implantation of (A) unloaded PEA fibers and (B) FGF9-loaded PEA fibers, double 
immunolabeled for endomucin (green) and NG2 (red). Quantitative estimation of (C) the 
number of endomucin+ arteriole-like microvessels at the skin side per high power field 
(40× objective), and (D) percentage of NG2+ microvessels normalized to the total number 
of endomucin+ microvessels per field (n = 9). Scale bar = 50 µm and arrows are pointing 
to endomucin/NG2+ microvessels (** p < 0.01). 
 
 
 131 
  
Polymer-based delivery vehicles offer great potential to deliver biologically active growth 
factors in a controlled fashion over a period of days to months to promote 
neovascularization [32-35]. Mooney and colleagues studied the use of injectable alginate 
hydrogel with PLGA microspheres for sequential delivery of VEGF and PDGF-BB in a 
myocardial infarction mouse model [36]. Cao et al. investigated the co-delivery of VEGF 
and PDGF-BB or the co-delivery of FGF2 and PDGF-BB, adsorbed onto heparinized 
sepharose beads embedded into Matrigel, to ischemic hindlimb model of rat and rabbit 
[37]. Formation of stable vasculature was observed for the co-delivery of FGF2 and PDGF, 
while vessel size and maturity was enhanced by sequentially delivering VEGF and PDGF 
[36-38]. However, VEGF can inhibit vessel maturation during PDGF-mediated 
angiogenesis [39]. Previous studies has shown that co-delivery of FGF2 and fibroblast 
growth factor-9 (FGF9) by the means of an osmotic pump to mouse ischemic hindlimb 
resulted in mature, persistent, and vasoreactive microvessels [40].  
As described in Chapter 4, FGF2 and FGF9 were dual-loaded into biodegradable 
electrospun poly(ester amide) (PEA) fibers, which showed enhanced endothelial tube 
formation, increased smooth muscle cell migration and improved endothelial cell-smooth 
muscle cell interaction in vitro [22]. Building up on the previous promising results, it was 
desired to investigate its efficacy in induction of mature neovessel formation using in vivo 
models.  FGF9 is a  mesenchyme-targeting growth factor that plays a crucial role in the 
recruitment of mural cells and the formation of physiologically mature and stable 
neovessels [40]. It acts mainly through sonic hedgehog signaling, an upstream regulator of 
PDGFRβ expression [40], and the PDGF-BB/PDGFRβ signaling pathway was reported to 
be pivotal to recruiting SMCs and pericytes to the developing vasculature [41]. Controlled 
delivery of FGF9 from PEA fibers will protect FGF9 from rapid degradation and clearance 
from the application site, which was a major challenge of the delivery of growth factors in 
a soluble form as a bolus injection or infusion in the systemic circulation or tissue of interest 
[42-46]. Moreover, controlled delivery of FGF9 from PEA electrospun fibers provides 
predictable release kinetics of the bioactive agent, which can boost its stability, allow its 
sustained release in a biologically active form and provide a more efficient means of 
application at the site of interest [21].  
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 Conclusion 
In this chapter, electrospun PEA fibrous mats as a controlled delivery vehicle for FGF2 
and FGF9 for potential therapeutic angiogenesis application, using two in vivo models, the 
CAM model (as a screening platform) and the ischemic hindlimb mouse model (as a 
pathological preclinical model) were evaluated. Localized angiogenesis was observed at 
the interface between the FGF-loaded fibrous mat and the CAM surface and there was a 
significant enhancement in the quality of vasculature in terms of increased amount of 
perfused blood as detected from the 3D power Doppler vascular quantification metrics 
(vascularization and vascularization flow indices) of the regions of interest of the CAM 
underneath the FGF-loaded PEA fibrous mats. Moving forward to a more clinically-
relevant model (the ischemic hindlimb model), the implantation of the FGF9-loaded PEA 
fibrous mats on the surface of infarcted TA muscle resulted in an increased mural cell-
wrapping of local microvessels compared to the unloaded fibers group as demonstrated by 
the H&E and double immunofluorescent staining. Taken together, FGF-loaded PEA 
electrospun fibers can have promising applications in therapeutic angiogenesis for 
treatment of ischemic vascular diseases and pre-vascularized tissue engineering. 
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Chapter 6  
6 General Discussion and Conclusions 
Overview: This chapter provides a summary of the research work and discusses the 
strengths and limitations of this work. Overall significance of the research work is 
highlighted and future directions are recommended. 
 
  Summary 
In therapeutic angiogenesis, the use of recombinant protein growth factors is a preferred 
therapeutic strategy compared with gene therapy, as it potentially offers a more 
straightforward treatment [1]. Angiogenic growth factors have been delivered either by 
bolus injection or infusion into the systemic circulation or the tissues of interest. However, 
the short half-life of these proteins results in a low local availability at the site of interest 
that represents the major challenge for angiogenic protein therapy [2]. One approach to 
overcome such limitation is the localized and sustained delivery of growth factors at the 
desired site from polymer-based delivery systems [3, 4].  
Hence, the focus of this research was to develop a controlled delivery system for the 
sustained release of angiogenic growth factors over a period of weeks to months in order 
to mimic the normal multifaceted angiogenic process and to exogenously augment it [5]. 
To that end, 8-Phe-4, a member of the biodegradable poly(ester amide) (PEA) family was 
utilized to fabricate electrospun nanofibers. The rationale for exploring PEAs is that they 
combine the favorable properties of both polyesters and polyamides – the tunability in the 
degradation rate via the ester groups and mechanical strength via the hydrogen bonding of the 
amide groups. The ester and amide linkages promote both hydrolytic and enzymatic 
degradation, which should ensure a surface degradation mechanism [6], and this provides 
better prediction and control over the release profile. In addition, PEAs with tailored 
degradation rates can be synthesized with the careful selection of the monomers. Their 
degradation by-products include amino acids, which are found physiologically, limiting 
their potential systemic toxicity [7]. Unlike polyesters, PEA degradation results in less 
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acidic by-products, avoiding significant pH decrease in the tissues and thus decreased host 
immune responses [8]. 
One or multiple growth factors can be loaded into PEA delivery vehicles, potentially 
sustaining their release, enhancing their therapeutic efficacy and accelerating favorable 
cell-material interactions. And the ultimate goal is to support the formation of functional 
and stable neovasculature. Electrospinnning is a versatile technique that can produce 
delivery vehicles with high surface area-to-volume ratio, which can prolong the angiogenic 
factor release and overcome difficulties encountered with angiogenic factor incorporation 
within conventional delivery systems, such as controlling the release profile and retaining 
growth factor bioactivity. Angiogenic growth factors were previously loaded into 
electrospun fibers using blending, emulsion and coaxial electrospinning [9-11], or through 
heparin immobilization onto electrospun scaffolds [12]. Controlled-release biodegradable 
polymeric fibers can serve as a simple, low-cost and efficient alternative for implantable 
mini-infusion pumps for the delivery of angiogenic growth factors, without the need of 
delivery system removal after depletion of the growth factor.  
Although stimulating angiogenesis using angiogenic growth factors is an essential first 
step, it might not be a sufficient condition for producing a stable neovasculature. The 
absence of mural cell coverage subjects newly formed vessels to regression; however, 
nascent vessels are stabilized and become resistant to regression once they are invested 
with pericytes [13]. To mimic the complex angiogenesis process, the delivery of more than 
one growth factor in a differential and sustained fashion is required in order to pattern 
neovessel maturation and to achieve functional vascular formation. Fibroblast growth 
factor-9 (FGF9), an arteriogenic growth factor, was recently reported to play a crucial role 
in the recruitment of mural cells and the formation of physiologically mature and stable 
neovessels [14]. It acts mainly through Sonic Hedgehog signaling, an upstream regulator 
of platelet-derived growth factor receptor-β (PDGFRβ) expression [14], and the PDGF-
BB/PDGFRβ signaling pathway was reported to be pivotal to recruiting mural cells to the 
developing vasculature [15]. When FGF9 was infused into ischemic mouse hindlimb, the 
resulting microvessels were found to be invested with more vascular smooth muscle cells 
than those generated in the absence of FGF-9. In addition, FGF-9 injection had led to 
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enhanced regeneration of the skeletal muscle, along with restoration of limb function [14, 
16]. Hence, FGF9 sustained delivery could potentially drive muscularization of angiogenic 
sprouts and help regenerate functional neovasculature in ischemic vascular disease 
patients. 
In the current work, a controlled delivery system for the sustained release of FGF9 has 
been developed utilizing electrospun PEA fibers fabricated by either blend or emulsion 
electrospinning technique. The morphological properties of the FGF-loaded fibers have 
been characterized using SEM and TEM. In vitro PEA matrix degradation, 
biocompatibility, in vitro FGF9 and FGF2 release kinetics, and bioactivity of the released 
growth factor were evaluated. RT-qPCR was employed to evaluate PDGFRβ gene 
expression in NIH-3T3 fibroblasts, 10T1/2 cells, and human coronary artery smooth 
muscle cells cultured on PEA fibers at different FGF9 concentrations. FGF9-loaded PEA 
fibers exhibited controlled release of FGF9 over 28 days with limited burst effect while 
preserving the FGF9 bioactivity. Electrospun PEA fibers were found to support the 
proliferation of fibroblasts for five days even in serum-depleted medium. Cells cultured on 
FGF9-supplemented PEA mats resulted in upregulation of PDGFRβ in concentration and 
cell type-dependent manner (Chapter 3). 
Subsequently, FGF2 and FGF9 were dual-loaded using a mixed blend and emulsion 
electrospinning technique, and exhibited differential and sustained-release from PEA fibers 
over 70 days with preserved bioactivity. In vitro angiogenesis assays showed enhanced 
endothelial cell (EC) tube formation and directed-migration of smooth muscle cells 
(SMCs) to PDGF-BB, and stabilized EC-SMC tube formation. FGF2/FGF9-loaded PEA 
fibers did not induce significant inflammatory response in vitro as shown by the low 
interleukin-8 mRNA expression of THP-1 human monocytic cell line or in vivo after their 
subcutaneous implantation into mice. Histological examination showed that FGF2/FGF9-
loaded fibers induced cell niche recruitment around the site of implantation. Furthermore, 
controlled in vivo delivery of FGF9 to mouse tibialis anterior muscle resulted in a dose-
dependent expansion of mesenchymal progenitor-like cell layers and ECM deposition 
(Chapter 4). 
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Lastly, FGF-loaded PEA fibers were evaluated using two in vivo models, the CAM model 
as a screening platform and the ischemic hindlimb mouse model as a pathological pre-
clinical model (Chapter 5). The CAM assay coupled with 3D power Doppler vascular 
quantification showed localized angiogenic effects at the regions underneath the FGF-
loaded fibrous mats, which could indicate the assembly of stable microvessels and 
increased blood flow in the CAM owing to the controlled release of FGF2 and FGF9. 
Moreover, the implantation of the FGF9-loaded PEA fibrous mats on the surface of 
infarcted tibialis anterior muscle resulted in an enhanced skeletal muscle regeneration and 
increased abundance of mural-wrapped microvessels compared with the unloaded fibers 
control group as demonstrated by the histological analysis. At Day 7 post-ischemia, there 
was no significant difference in terms of usage of the injured limb for weight bearing, 
between the injured limbs treated with FGF9-loaded fibers compared with those treated 
with unloaded PEA fibers. Longer time-point studies (28 days) are proposed to evaluate 
the effect of controlled delivery of FGF9 on reversing ischemia and restoration of function. 
 
 Strengths and Limitations 
Firstly, although PEAs have been electrospun previously from alanine and phenylalanine [17, 
18], smaller average fiber diameter (~ 250 nm) was achieved with electrospinning of 8-Phe-4, 
due to the higher molecular weight of the synthesized polymer by interfacial polymerization, 
and subsequent reduction in the concentration of the polymer required for reaching the optimal 
viscosity needed for electrospinning. This would impart increased surface area-to-volume 
ratio, which facilitates improved drug loading. The solution and processing parameters were 
optimized for fabricating defect-free fibers.  
Secondly, although model compounds have been previously loaded into PEA ultrafine fibers 
[17, 18], this study demonstrated the versatility of PEA electrospun fibers as a controlled 
delivery vehicle for different bioactive molecules (bovine serum albumin, FGF2 and FGF9) 
with varying molecular weights (from 14 kD to 60 kD), and dual loading of two growth factors 
using mixed blend and emulsion electrospinning techniques. Also, the bioactivity of the 
released growth factors and their in vitro release kinetics have been investigated. The surface 
erosion degradation mechanism of PEA fibers was studied and correlated to the in vitro release 
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profile of the growth factors. The in vitro biocompatibility of the developed 3D scaffold have 
been assessed and the PEA fibrous scaffolds demonstrated positive interaction with different 
types of cells (NIH 3T3 fibroblasts, C3H 10T1/2 cells and human coronary artery smooth 
muscle cells (HCASMC)) in terms of attachment, spreading and proliferation. 
Another strength of this study is the evaluation of the induced host immune response in vitro 
using human monocytes followed by analysis of gene expression of a targeted inflammatory 
marker (Interleukin 8), and in vivo by subcutaneous implantation of the fibrous mats in mice. 
PEA fibers neither elicited inflammatory responses nor induced scar formation. Although 
inflammation is usually associated with a biomaterial implantation in a host and negative 
outcomes (e.g., fibrosis and implant rejection) might take place, some inflammatory reactions 
can have positive outcomes that can promote biomaterial-tissue integration and regeneration 
[19, 20]. Notwithstanding that, severe induced inflammation and host response often preclude 
many synthetic biomaterials from growth factor delivery applications [21]. 
Moreover, the angiogenic capacity of the FGF-loaded PEA fibers have been evaluated through 
in vitro angiogenesis assays (Matrigel tube formation and directed migration assays). 
Treatment with FGF2/FGF9-loaded PEA fibers showed enhanced tube formation and directed 
migration of HCASMC towards a chemotactic agent PDGF-BB, as well as increased 
interaction between ECs and SMCs. Also, it was evaluated in vivo using two models; the chick 
chorioallantoic membrane (CAM) assay, as a quick screening platform, and the ischemic 
hindlimb mouse model as a pathological model. The CAM assay demonstrated a localized 
angiogenic effect due to the controlled release of FGF2 and FGF9, and 3D power Doppler 
vascular quantification showed improvement in the quality of microvessels in terms of blood 
perfusion in the local microenvironment underneath the fibrous mat. In the ischemic hindlimb 
mouse model, injured limbs treated with FGF9-loaded PEA mats resulted in an enhanced 
regeneration of the ischemic skeletal muscle with reduced inflammation and minimal tissue 
necrosis, and increased abundance of mural-covered microvessels.   
The CAM model was simple and it provided a better physiological system for in vivo 
analysis than the in vitro assays, but it had some limitations in detecting a significant 
increase in vascular density of the full CAM vasculature due to its rapid vascular growth 
that outpaced the controlled and relatively slow release of FGF2 and FGF9 from the PEA 
 142 
  
fibers. In addition, the released amount of growth factors from the fibers might not have 
reached the effective therapeutic dose to induce significant angiogenesis in the full CAM 
surface.  
The histological analysis of the ischemic hindlimb mouse model showed promising initial 
results 10 days after implantation of the FGF9-loaded fibers in terms of enhanced 
regeneration of the ischemic skeletal muscle and increased abundance of mural-covered 
microvessels.  The CatWalk gait analysis for the mice treated with FGF9-loaded fibrous 
mats did not show superior restoration of function of the injured limb when compared with 
the group treated with unloaded fibers. Detection of significant differences at Day 7 post-
ischemia in terms of functional recovery of the injured limbs might be early. In view of 
this, longer time-point studies (28 days) are proposed in order to evaluate the effect of 
controlled delivery of FGF9 on reversing ischemia and restoration of function. 
 
 Future Directions 
This study investigated the utility of electrospun PEA fibers for dual and sustained delivery 
of FGF2 and FGF9 for therapeutic angiogenesis application and the data collectively 
indicated that they are promising candidates. In order to advance to the level of angiogenic 
therapy clinical studies, the aforementioned limitations with the current study, including 
rapid vascular growth of the CAM model that outpaced the controlled and slow release of 
FGF2 and FGF9 from the PEA fibers and the CatWalk gait analysis for Day 7 post-
ischemia study that was not able to detect superior restoration of injured limb function for 
the FGF9-loaded fibers treated mice, have to be addressed. And to that end: 
 Longer time-point ischemic hindlimb mouse study (28 days) is proposed in order 
to evaluate the effect of controlled delivery of FGF9 on reversing ischemia and 
restoration of function.  
 Ischemic hindlimb perfusion can be assessed by laser Doppler perfusion imaging 
and a perfusion ratio can determined by dividing the mean perfusion value of the 
dorsal side of the ischemic limb by that of the identical region of the non-ischemic 
limb of the mouse.  
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 RT-qPCR analysis can be employed for in vivo samples to evaluate the mRNA 
expression of other inflammatory markers, such as interleukin-6 (IL-6), interleukin-
1 (IL-1), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-gamma), 
together with specific immunohistochemical staining of inflammatory cells (such 
as CD68, CD163 and F4/80). 
 Studying the release kinetics and diffusion pattern of FGF9 in vivo from the PEA 
fibers to the infarcted muscle and determining the concentration gradient across 
different regions of the tibialis anterior muscle from the skin side to the bone side 
is recommended, which may provide better understanding about the therapeutic 
efficiency of the released FGF9 in vivo. 
 Deeper in vivo investigation of the signaling pathway via which FGF9 controls the 
mural cell-wrapping of microvessels building on the signaling cascade proposed by 
Frontini et al. [14], by conducting RT-qPCR and Western blot protein analyses of 
selected signaling molecules other than PDGFR-.  
 The use of alternative ischemic models is also suggested, such as myocardial 
infarction models of larger animals (e.g., canine and porcine models), in order to 
better mimic the clinical situation of ischemic vascular disease and have a more 
comprehensive investigation of the effects of the controlled delivery of FGF9 on 
targeting neovessel maturation. 
 
 Significance 
This study provides a novel strategy of using amino acid-based biodegradable poly(ester 
amide)s to fabricate electrospun fibrous scaffolds for sustained-release of single or multiple 
angiogenic growth factors, thus providing a means for minimally invasive 
revascularisation technique as the next advance in the treatment of ischemic vascular 
diseases. 
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